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Umbilical cord blood (UCB) is an important source of hematopoietic stem cells (HSC) for
allogeneic transplantation when HLA-matched sibling and unrelated donors (MUD) are
unavailable. Although the overall survival results for UCB transplantation are comparable
to the results with MUD, UCB transplants are associated with slow engraftment, delayed
immune reconstitution, and increased opportunistic infections. While this may be a con-
sequence of the lower cell dose in UCB grafts, it also reflects the relative immaturity of
cord blood. Furthermore, limited cell numbers and the non-availability of donor lymphocyte
infusions currently prevent the use of post-transplant cellular immunotherapy to boost
donor-derived immunity to treat infections, mixed chimerism, and disease relapse. To fur-
ther develop UCB transplantation, many strategies to enhance engraftment and immune
reconstitution are currently under investigation.This review summarizes our current under-
standing of engraftment and immune recovery following UCB transplantation and why
this differs from allogeneic transplants using other sources of HSC. It also provides a
comprehensive overview of promising techniques being used to improve myeloid and lym-
phoid recovery, including expansion, homing, and delivery of UCB HSC; combined use
of UCB with third-party donors; isolation and expansion of natural killer cells, pathogen-
specific T cells, and regulatory T cells; methods to protect and/or improve thymopoiesis.
As many of these strategies are now in clinical trials, it is anticipated that UCB transplan-
tation will continue to advance, further expanding our understanding of UCB biology and
HSC transplantation.
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INTRODUCTION
Over the last 25 years, umbilical cord blood (UCB) has become an
established alternative source of hematopoietic stem cells (HSC)
for use in allogeneic HSC transplantation (1, 2). Due to the
lower immunogenicity of UCB grafts and the low rates of graft-
versus-host disease (GvHD) compared to bone marrow (BM)
and peripheral blood stem cell (PBSC) transplants, less stringent
HLA-matching has traditionally been required (3–5). At present,
only HLA typing at HLA-A and -B (serological) and HLA-DRB1
(allelic) are commonly used, with mismatches at one or two loci
usually being tolerated if sufficient cell doses are transplanted
(6). Consequently, UCB transplantation is a potential treatment
option for many patients who lack a suitable HLA-matched sib-
ling or unrelated donor. With over 600,000 frozen cord blood
units (CBU) stored in cord blood banks worldwide, UCB also
has the advantage of being immediately available, avoiding long
delays to transplantation, and without any associated risks to the
donors (2).
While UCB has increased the applicability of HSC transplanta-
tion, UCB transplantation can be associated with delayed engraft-
ment, poor immune reconstitution, and higher rates of infection
compared to conventional sources of HSC (4, 5, 7–9). This is due
to the quantitative and qualitative differences in the composition
of UCB grafts (10). While UCB contains a higher concentration
of HSC than adult peripheral blood (PB), each unit contains a one
to two log lower total cell dose compared to BM and PBSC har-
vests (PBSCH). Furthermore, the vast majority of T cells within
UCB are antigen-inexperienced, i.e., naïve (CD45RA+), being less
responsive to allogeneic stimulation, having reduced expression
of transcription factors associated with T-cell activation (e.g.,
nuclear factor of activated T cells, NFAT), and producing lower
levels of effector cytokines compared to activated T cells from
adult PB (11–13). UCB also contains more immunoregulatory
cells, including regulatory T cells (Tregs), with greater potential for
expansion and increased suppressive function compared to adult
Tregs (13–15). The immaturity of UCB dendritic cells is also asso-
ciated with lower antigen presenting activity, reduced expression
of co-stimulatory molecules (CD80, CD86), reduced cytokine pro-
duction (TNFα, IL-12), and an inherent ability to induce immune
tolerance through peripheral expansion of Tregs (13, 16, 17).
Within this review, the pattern and factors affecting engraft-
ment and immune reconstitution following UCB transplantation
will be summarized. We will then provide an overview of current
strategies being used to improve engraftment and immune recon-
stitution following UCB transplantation and potential areas for
future research and development (Table 1).
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Table 1 | Methods to improve engraftment and immune reconstitution
in UCB transplantation.
1. INCREASING CELL DOSE
Improved collection and processing of cord blood
Infusion of two cord blood units (double cord blood transplantation)
Ex vivo expansion of cord blood HSC/HPC
Infusion of cord blood with third-party donor cells (haploidentical graft)
2. IMPROVING DELIVERYAND HOMING OF HSC
Direct intrabone infusion of cord blood
Increased stromal-derived factor-1 (SDF-1) (CXCL12)/CXCR4 interaction
(e.g., inhibition of CD26 peptidase)
Ex vivo fucosylation of HSC/HPC
3. IMPROVING SELECTION OF CORD BLOOD UNITS
Enhanced HLA-matching
Detection of donor specific anti-HLA antibodies
4. MODIFYING UCBTRANSPLANT REGIMENS
Using reduced-intensity conditioning
Using T-replete protocols
5. EXPANDING SPECIFIC CELL POPULATIONS (EXVIVO OR INVIVO)
Natural killer (NK) cells
T cells/pathogen-specific T cells (CMV, EBV, adenovirus)
Regulatory T cells (Tregs)
6. CO-INFUSING CORD BLOODWITHACCESSORY CELLS
Mesenchymal stem cells (MSC)
7. IMPROVINGTHYMOPOIESIS
Interleukin-7 (IL-7), interleukin-2 (IL-2), and interleukin-15 (IL-15)
Reducing sex steroid hormones (androgen, estrogen)
Growth hormone (GH), insulin-like growth factor 1 (IGF-1)
Keratinocyte growth factor (KGF)
Tyrosine kinase inhibition (sunitinib)
FMS-like tyrosine kinase receptor III ligand (FLT-3-L)
Stem cell factor (SCF)
Inhibition of p53 [pifithrin-β (PFT-β)]
HSC, hematopoietic stem cells; HPC, hematopoietic progenitor cells; UCB,
umbilical cord blood; HLA, human leukocyte antigen.
PATTERN AND KINETICS OF ENGRAFTMENT AND IMMUNE
RECONSTITUTION FOLLOWING UCB TRANSPLANTATION
NEUTROPHIL AND PLATELET ENGRAFTMENT
Following conditioning [chemotherapy and/or total body irradi-
ation (TBI)] and infusion of the UCB graft, there is an initial
period of aplasia during which time the donor UCB HSC and
early hematopoietic progenitors engraft, differentiate, and prolif-
erate within the BM environment. The total nucleated cell (TNC)
dose and/or CD34+ cell dose within the UCB unit(s) (per recipient
body weight) are important contributing factors to the probabil-
ity and rate of neutrophil and platelet engraftment (6, 18). UCB
grafts contain a lower TNC dose compared to BM and PBSCH and,
therefore, the time to neutrophil engraftment (defined as the first
of three consecutive days with a neutrophil count >0.5× 109/l)
is prolonged, with a median time of approximately 30 days for
UCB, 21 days for BM harvests, and 14 days for PBSCH (19). Sim-
ilarly, platelet recovery in UCB transplantation is also prolonged
with a median time to engraftment (defined as the first of three
consecutive days with an unsupported platelet count>20× 109/l)
ranging from 50 to 100 days. Other important factors influencing
engraftment are the degree of HLA-matching, the intensity of the
conditioning regimen, and the type of immunosuppression used
for GvHD prophylaxis (20).
CORD BLOOD NK CELLS: PROPERTIES AND RECOVERY AFTER UCB
TRANSPLANTATION
In keeping with allogeneic HSCT using BM or PBSCH, lym-
phocyte reconstitution following UCB transplantation typically
begins with rapid recovery of natural killer (NK) cells (21)
(Figure 1). UCB contains both main NK-cell populations found
in PB, i.e., CD16+CD56dim and CD16−CD56bright, although dif-
ferences in their phenotype, maturity, and function have been
reported (22, 23). UCB also contains precursor NK-cell popu-
lations, including CD16+CD56− cells (24). UCB NK cells have
lower cytotoxicity, although their function can be enhanced fol-
lowing interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12
(IL-12) or interleukin-15 (IL-15) stimulation (22). They also
have lower expression of critical adhesion molecules, e.g., CD2,
CD54, and L-selectin, and higher expression of inhibitory recep-
tors including killer-cell immunoglobulin-like receptor (KIR) and
NKG2A/CD94 (23). Post-UCB transplant, NK-cell recovery ini-
tially occurs through expansion of CD16−CD56bright cells with
total NK-cell numbers returning to normal values within the
first 3 months (21, 25, 26). Beyond this, UCB transplantation is
then associated with an increase in both the absolute number and
proportion of CD16+CD56dim cells compared to BM transplan-
tation (27). Total NK-cell numbers may temporarily exceed the
normal range seen in the healthy population, possibly through
a compensatory expansion that occurs during periods of pro-
found T-cell lymphopenia (28). This pattern has been reported in
both children and adults, following single and double UCB trans-
plants [NK cells are derived from the predominant unit in the
case of double UCB transplantation] and can last up to 9 months
post-transplantation (21, 25, 26).
CORD BLOOD T CELLS: PROPERTIES AND RECOVERY AFTER UCB
TRANSPLANTATION
In allogeneic HSCT, T-cell reconstitution typically occurs in two
phases (Figure 1). The first involves early allo-antigen driven
homeostatic proliferation of memory T cells, contained either
within the graft or, in the setting of T-cell depleted grafts, from
residual host T cells escaping pre-transplant conditioning ther-
apy (“thymic-independent”). This, however, produces a restricted
T-cell population with limited T-cell receptor (TCR) repertoire
against infection. Homeostatic proliferation also occurs faster in
CD8+ T cells compared to CD4+ T cells, producing a reversal
of the normal CD4:CD8 T-cell ratio (9, 19). In contrast to BM
and PBSCH, UCB mainly contains antigen-inexperienced naïve
T cells. Early T-cell reconstitution can therefore only occur via
the more stringent in vivo priming, activation, and proliferation
of the limited naïve T-cell repertoire contained within the graft.
The immaturity of UCB T cells is also associated with reduced
effector cytokine expression (IFNγ, TNFα) and reduced expres-
sion transcription factors involved in T-cell activation (NFAT,
STAT4, and T-bet) (11). Consequently, longitudinal studies of
immune reconstitution in UCB transplantation have consistently
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FIGURE 1 | Kinetics of immune reconstitution and transplant-related
complications in children following UCB transplantation. The
post-transplantation period can be divided in three phases. The
pre-engraftment period (Phase I, days 0–30) is characterized by general
immunosuppression (i.e., depletion of lymphocytes in the recipient by ATG),
neutropenia, low platelet counts, and high susceptibility to fungal infections.
Host residual APCs progressively disappear during Phase I. Massive
proliferation leads NK cells to reach normal levels within 1 month
post-transplantation. They may represent 80% of the recipient’s PBLs during
the post-engraftment period (Phase II, days 31–100). During Phase II, patients
experience high susceptibility to bacterial infections, viral infections (i.e.,
CMV), and acute GvHD. Some UCB T cells are believed to persist in the
recipient and proliferate through HE. This period culminates with the de novo
generation of T cells through thymopoiesis and the end of the 100-day
high-risk window. The late phase (Phase III) is characterized by a higher
incidence of VZV infection/reactivation and a progressive reconstitution of B
cell and T-cell subsets, which can reach normal levels at 6–9 months post-
transplant [figure and legend originally published by Merindol and colleagues
(226); used with the permission of H. Soudeyns and the Journal of Leukocyte
Biology (Copyright FASEB Office of Publications, Bethesda, MD, USA)].
demonstrated profound early T-cell lymphopenia with impaired
functional immunity and limited responses to viral infections, in
keeping with a primary immune response (9, 28–30).
For long-term effective immune reconstitution with a broad T-
cell repertoire, a second T-cell expansion phase is necessary involv-
ing thymic production of new naïve T cells (“thymic-dependent”).
Hematopoietic progenitors, produced from the engrafted HSC
within the BM, enter the thymus to form early T-cell progenitors
(ETPs). During T-cell development in the thymus, double posi-
tive thymocytes (CD4+CD8+) are exposed to self-MHC on the
thymic cortical epithelial cells. Only those thymocytes that bind
to self-MHC with appropriate affinity will be “positively” selected
to continue their development into single positive T cells; CD4+
T cells interact with MHC Class II molecules, CD8+ T cells inter-
act with MHC Class I molecules. Double positive thymocytes that
bind too strongly or too weakly to self-MHC undergo apoptosis.
As the thymocytes pass through the thymic medulla they are then
exposed to self-antigens presented in association with self-MHC
molecules. Thymocytes that bind to self-antigens are removed by
“negative” selection, thus preventing the production of autore-
active T cells (31). The presence of naïve T cells with markers
of recent thymic emigration, i.e., T-cell receptor rearrangement
excision DNA circles (TRECs), usually begins around 3–6 months
post-UCB transplant (32, 33). However, the timing and effec-
tiveness of thymopoiesis can be impaired by age-related thymic
atrophy and/or thymic damage from conditioning therapy and
GvHD. Escalon and Komanduri reported a longer delay in the
recovery of thymopoiesis, as measured by TREC, in UCB trans-
plantation compared to other HSC sources, possibly due to the
limited dose of lymphoid progenitors within the UCB grafts (30).
As a consequence, T-cell reconstitution was delayed with a median
time to recovery of approximately 9 months for CD8+ cytotoxic
T cells and 12 months for CD4+ helper T cells (25). Similarly,
in a retrospective Eurocord analysis of 63 children transplanted
with related and unrelated UCB grafts, the median time to T-cell
reconstitution was 8 months for CD8+ T cells and 12 months for
CD4+ and total T cells (21). Factors favoring T-cell recovery were
HLA-matched UCB, higher nucleated cell dose, and positive recip-
ient cytomegalovirus (CMV) serology prior to transplantation.
Conversely, the presence of acute GVHD delayed T-cell recovery.
Interestingly, in a recent Eurocord study of children with severe
combined immunodeficiency (SCID) transplanted with either
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UCB (n= 74) or haploidentical grafts (n= 175), there were no
significant difference in T-cell recovery (total T cells and CD4+ T
cells) between the groups at any time, although the UCB transplant
recipients had significantly faster recovery of total lymphocyte
counts (34).
Over the last few years, the use of double cord blood trans-
plants has significantly increased, mainly in adults following
reduced-intensity conditioning (RIC) regimens. In this setting,
although two CBUs are initially transplanted, only one provides
prolonged engraftment, i.e., the “predominant” unit. Few studies
have reported data on T-cell recovery after double CBT. Ruggeri
and colleagues reported outcomes, infection rates, and immune
reconstitution after 35 double UCB transplants in recipients with
high-risk hematological diseases (25). Lymphocyte subset analy-
ses were performed at 3, 6, 9, and 12 months post-transplant and
demonstrated reduced T and B cell counts until 9 months. Recov-
ery of thymopoiesis, as measured by TRECs, was also impaired
until 9 months post-transplant. Somers and colleagues also ana-
lyzed engraftment kinetics in leukocyte subsets following non-
myeloablative double UCB transplants (26). CD4+ T cells,CD8+ T
cells, and NK cells all showed early engraftment predominance by
day 11, followed by predominance in myeloid cells by day 18. Based
upon these findings, it is proposed that T cells and/or NK cells from
the predominant unit may elicit an early immune response against
the second unit.
CORD BLOOD B CELLS: PROPERTIES AND RECOVERY AFTER UCB
TRANSPLANTATION
B cell reconstitution occurs over the first 6 months post-UCB
transplantation, although full recovery of immunoglobulins takes
longer (Figure 1). In 63 children given related or unrelated UCB
transplants, the median time to B cell recovery was 6 months
(21). PB CD19+CD28highCD38high transitional B cells are first
detectable at 1–2 months post-transplant. Over the next 3–
6 months, total B cell numbers gradually rise with an associ-
ated increase in the proportion of mature CD19+CD28intCD38int
mature B cells to approximately 90% by 9 months (35). As reported
with NK cells, total B cell numbers may also expand above the
normal range during the period of T-cell lymphopenia before
returning to normal values when T-cell recovery occurs (28). At
the same time, levels of immunoglobulins to commonly encoun-
tered antigens typically rise to normal levels by the end of the
first year. Recovery of B cell function, as measured by the time
to discontinuation of intravenous immunoglobulin replacement
therapy, was compared following UCB (n= 74) and haploidenti-
cal transplants (n= 175) in children with SCID (34). At 3 years
after transplantation, 45% of the UCB transplant recipients had
discontinued immunoglobulins, compared with 31% of the hap-
loidentical recipients (P = 0.02). Other factors associated with
improved B cell function were the absence of pre-transplantation
infections and use of myeloablative conditioning (MAC).
IMPLICATIONS OF DELAYED IMMUNE RECONSTITUTION
FOLLOWING UCB TRANSPLANTATION
As a direct consequence of delayed immune reconstitution, UCB
transplantation is associated with a significant risk of oppor-
tunistic infections, particularly viral infections including CMV,
varicella zoster virus (VZV), Epstein–Barr virus (EBV), aden-
ovirus (ADV), human herpesvirus-6 (HHV-6), and BK virus
(Figure 1). In a recent retrospective review of 332 UCB trans-
plants performed at the University of Minnesota between 1994
and 2007, 51% of CMV-seropositive patients (n= 92/180) expe-
rienced CMV reactivation, with a median time to reactivation of
40 days (range, 9–95 days) (36). CMV infection was infrequent
in CMV-seronegative recipients (1.3%, n= 2/152). Neither pre-
transplant CMV-seropositive status nor CMV reactivation was
associated with increased transplant-related mortality (TRM).
However, in the 14% (n= 25/180) of CMV seropositive patients
that developed CMV disease (16 respiratory; 6 gastrointestinal; 3
multi-organ), TRM was significantly higher and overall survival
reduced. It is hypothesized that the high incidence of CMV reacti-
vation/infection post-UCB transplantation is related to impaired
CMV-specific T-cell responses. In a study of T-cell reconstitution
in 28 pediatric UCB transplants using MAC, CD4+ and CD8+ T
cells were persistently low for the first 3 months post-transplant
(37). By 3 months, only two patients had developed CMV-specific
T cells and only one patient had VZV-specific T cells, as measured
by antigen-specific IFNγ ELISPOTS. CMV and VZV responses
developed over the next 3 years in 30% and 40% of the recipients,
respectively. However, development of CMV or VZV disease was
not necessary to acquire these responses and no subject devel-
oped infections once satisfactory responses had been attained
(>150 spot forming units/106 PBMC). More recently, McGoldrick
and colleagues were able to demonstrate CMV-specific polyclonal
CD4+ and CD8+ T-cell responses from the donor UCB graft by
day 42 but at insufficient numbers to be able to control viral reac-
tivation (38). The lack of sufficient CMV-specific CD8+ T cells to
control CMV reactivation appears to be due to insufficient in vivo
expansion, either due to immunosuppressive therapy and/or early
deficiency of CD4+ T cells. Later control of CMV reactivation was
due to improved function of the T cells primed early after trans-
plant rather than de novo responses from the thymic-dependent
pathway.
In a retrospective study of EBV reactivation, 4.5% (n= 15/335)
patients receiving an UCB transplant between 1994 and 2005
developed EBV related complications (4 viremia; 11 PTLD) (39).
More recently, in a retrospective Eurocord study of 175 UCB trans-
plants in which EBV viral load was monitored by RT-PCR during
the first 3 months post-transplant, 24 patients had EBV reactiva-
tion with a median time of 86 days (range, 14 days to 2.7 years)
(40). The cumulative incidence of EBV reactivation by 100 days
was 8% (n= 15) and four patients developed EBV-PTLD (cumula-
tive incidence 2%) at a median time of 73 days (range, 63–80 days)
(median of 28 days after the first positive EBV RT-PCR result).
Other viral infections also have a higher prevalence in UCB trans-
plants compared to BM and PBSCH. VZV reactivation is more
frequent in UCB transplantation than BM transplants [RR 2.27
(95% confidence interval (CI), 1.18–4.34), P = 0.013], as is VZV
dissemination (41). HHV-6 is a double stranded DNA virus that
can reactivate following HSCT and may cause encephalitis and/or
pneumonitis. In a recent meta-analysis, the prevalence of HHV-6
reactivation and HHV-6 encephalitis was higher in patients receiv-
ing UCB than other stem cell sources (72 vs. 37%, P < 0.0001; 8 vs.
0.5%, P < 0.0001, respectively) (42). BK virus is another double
Frontiers in Immunology | Alloimmunity and Transplantation February 2014 | Volume 5 | Article 68 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
stranded DNA virus, belonging to the polyomavirus family, and
has been associated with hemorrhagic cystitis post-HSCT. A ret-
rospective analysis of 209 HSCT demonstrated that both BK PCR
positivity pre-transplant and receiving an UCB or haploidentical
graft with MAC was associated with a significantly higher risk of
developing hemorrhagic cystitis (43).
Opportunistic infections are associated with significant mor-
tality following UCB transplantation and are a major contributing
factor in >40% of deaths following UCB transplants, particularly
in the first 3 months (5, 7). In a review of 330 single unit UCB
transplants at Duke University, 110 patients died within the first
6 months, of which 58% were due to opportunistic infection (viral,
fungal, or protozoal) (9). Twenty-two patients died from ADV
and 12 from CMV infection. In a Grupo Español de Trasplante
Hematopoyético (GETH) study of 192 consecutive adult unre-
lated allogeneic HSCT, the 100-day and 3-year infection-related
mortality (IRM) for UCB transplants (n= 48) was 30% (95% CI,
10–40%) and 40% (95% CI, 12–58%), respectively (44). How-
ever, although IRM post-UCB transplantation remains a concern,
it is unclear whether UCB transplantation has a higher pro-
portion of deaths due to infection compared to other forms of
HSCT. In an IBMTR comparison of unrelated donor transplants
for leukemia, Laughlin and colleagues reported the proportion
of deaths due to infection within 100 days as 45, 21, and 24%
(P = 0.01) for UCB (n= 150), HLA-matched marrow (n= 367),
and HLA-mismatched marrow (n= 83), respectively (8). How-
ever, Rocha and colleagues observed that a similar proportion of
transplant deaths were due to infection when comparing cord
blood (42%, 18/62) to unrelated BM (41%, 41/320) (5). In the
Spanish GETH study, although UCB transplants had a higher risk
of severe infection compared to BM/PBSC transplants (85 vs. 69%,
P < 0.01), the 100-day IRM (30 vs. 28 vs. 22%; P = 0.2) and 3-year
IRM (40 vs. 42 vs. 38%, P = 0.5) were not significantly different
(44). Likewise, in a study of 136 pediatric unrelated donor trans-
plants, the proportion of patients in which infection was causal
or contributing toward death was not significantly different (BM
36%, T-cell depleted BM 33%, UCB 30%) (45).
IMPROVING ENGRAFTMENT AND IMMUNE
RECONSTITUTION FOLLOWING UCB TRANSPLANTATION
USE OF DOUBLE CORD BLOOD TRANSPLANTATION
In UCB transplantation, the cell dose (TNC dose and/or CD34+
dose) and HLA-matching of the graft are important factors
for successful engraftment in both pediatric and adult patients
(3, 5, 7). Therefore, in 2009, Eurocord published recommen-
dations for selection of CBUs for transplantation (6). In sum-
mary, when a single CBU (6/6 or 5/6 HLA-matched) does not
contain sufficient number of cells (TNC >2.5× 107/kg upon
freezing; >2.0× 107/kg on thawing), double cord blood trans-
plantation should be considered, aiming for a combined TNC
dose >3.0× 107/kg. Even higher doses are recommended if the
single CBU is only 4/6 HLA-matched (TNC >3.5× 107/kg upon
freezing;>2.5× 107/kg on thawing for malignant disorders; TNC
>4.0× 107/kg upon freezing;>3.5× 107/kg on thawing for non-
malignant disorders). UCB transplants using two units from dif-
ferent donors were first reported in 2001 by the Minneapolis group
in an attempt to increase cell dose infused in adults and older
children (46). Both units contribute to early engraftment, although
eventually, one unit predominates (47). In an analysis of 23 dou-
ble UCB transplants following MAC, hematopoiesis was observed
from a single donor in 76% patients at day 21 and 100% patients
by day 100 (48). Likewise, on review of 81 patients with sustained
chimerism after receiving a double UCB transplant using a non-
myeloablative regimen, single donor chimerism was detectable in
57, 81, and 100% patients at day 21, 100, and 365, respectively
(47). Double UCB transplants show high rates of engraftment
(85–100%) with the median time to neutrophil engraftment rang-
ing from 9 to 33 days depending on the conditioning regimen
and/or the use of granulocyte colony stimulating factor (GCSF)
(26, 47, 49). Interestingly though, a significant difference in the
rate of engraftment has not been demonstrated between patients
receiving one or two CBUs (47, 50). However, a lower relapse
risk was found in patients receiving two CBUs for acute leukemia
(CR1/CR2), possibly through an enhanced graft-versus-leukemia
(GvL) effect (50). Recently, Ruggeri and colleagues reported the
outcomes of 35 double cord blood transplants in recipients with
high-risk hematological diseases (25). The cumulative incidence
of neutrophil recovery was 86%, acute GvHD 47%, and first viral
infection 92%. Immune recovery was delayed with reduced T and
B cell counts and compensatory expansion of NK-cells observed
until 9 months post-transplant, followed by the appearance of new
thymic precursors.
CORD BLOOD EXPANSION
An alternative approach being used to increase cell dose in UCB
transplantation is ex vivo expansion of cord blood. As well as
increasing the total number of HSC cells for long-term engraft-
ment, this may also increase the number of committed progenitors
to reduce the initial period of neutropenia. Ex vivo expanded CB
can then be given alone or in combination with an unmanipu-
lated unit. In this setting, although the expanded unit improves
early hematopoietic recovery, it is the unmanipulated unit that
usually provides long-term engraftment (51). UCB expansion has
been achieved using several different methods. The first is liquid
culture in which isolated CD34+ or CD133+ HSC are expanded
in the presence of selected cytokines and growth factors, includ-
ing stem cell factor (SCF), thrombopoietin (TPO), GCSF, and/or
FMS-like tyrosine kinase 3 ligand (FLT-3-L) (52, 53). The opti-
mal milieu of cytokines and growth factors remains uncertain
but several groups have shown improved expansion by the addi-
tion of IL-3 and/or IL-6 (54). Shpall and colleagues performed
a feasibility study in which CD34+ cells were isolated from a
fraction (40–60%) of the CBU and expanded in liquid culture
with SCF, GCSF, TPO, and megakaryocyte growth and differen-
tiation factor (52). The remainder of the unit was then infused
with the expanded cells following MAC. The median TNC dose
infused was 0.99× 107/kg and the median time to engraftment was
28 days (range, 15–49 days) for neutrophils and 106 days (range,
38–345 days) for platelets. Using a modification to this approach,
a Phase I/II trial was performed in which CD133+ cells were iso-
lated from a portion of the CBU and expanded in liquid cultures
with SCF, FLT-3-L, IL-6, TPO, and the copper chelator TEPA (55).
The median TNC fold expansion was 219 (range, 2–260). Both
expanded and unexpanded cells were infused with a median TNC
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of 1.8× 107/kg. Nine of the 10 patients engrafted with a median
time to neutrophil and platelet engraftment of 30 days (range, 16–
46 days) and 48 days (range, 35–105 days), respectively. Delaney
and colleagues reported results from a Phase I trial using an immo-
bilized Notch ligand Delta-1 in addition to SCF, FLT-3-L, TPO,
IL-3, and IL-6 (56). Ten patients with high-risk leukemia were
treated with a myeloablative double UCB transplant in which one
unit was expanded using this protocol. The average fold expansion
was 562 (range, 146–1496) for TNC and 164 (range, 41–471) for
CD34+ cells. Nine of the 10 patients engrafted with a median time
to neutrophil engraftment of 16 days (range, 7–34 days). However,
in contrast to other reported studies, there was a predominance
for donor CD33+ and CD14+ cell engraftment from the expanded
unit.
The second expansion method uses co-culture with a support-
ing network of mesenchymal stromal cells to provide a hematopoi-
etic microenvironment that supports HSC proliferation (57). de
Lima and colleagues reported the results of 31 patients receiv-
ing 2 CBUs, 1 of which was expanded ex vivo with mesenchy-
mal stem cells (MSC). This ex vivo culture system expanded
TNC and CD34+ cells by a median factor of 12.2 and 30.1,
respectively, and the median TNC dose infused was 8.34× 107/kg
(51). Of the 24 patients who received ex vivo expanded cells, 23
achieved neutrophil engraftment, at a median time of 15 days
(range, 9–42 days), and 18 had sustained platelet engraftment,
at a median time of 42 days (range, 15–62 days). Both com-
pared favorably to 80 CIBMTR historical controls that received
unmanipulated double UCB transplants only [neutrophil engraft-
ment 24 days (range, 12–52 days), P < 0.001; platelet engraftment
49 days (range, 18–264 days), P = 0.03]. In addition, while the
expanded CBU improved early hematopoietic recovery, in all cases,
the unmanipulated unit provided long-term engraftment.
HSC expansion has also been achieved using a continuous per-
fusion culture system in which cells are supplied with fresh culture
media and gaseous exchange (58, 59). In a Phase I study, Jaroscak
and colleagues expanded a portion of a CBU using a continuous
perfusion culture device and infused these expanded cells 12 days
after the remainder of the original unit (58). The median fold
increase in TNC was 2.4 (range, 1.0–8.5). Twenty-one of the 26
patients attained neutrophil engraftment with a median time of
22 days (range, 13–40 days). The median time for platelet engraft-
ment was 71 days (range, 39–139 days; n= 16). Ongoing early
phase clinical trials of all three methods are in progress.
COMBINED USE OF UCB WITH THIRD-PARTY DONOR
Another strategy being used to improve engraftment following
UCB transplantation is the combined use of cord blood and hap-
loidentical transplants (60, 61). While the haploidentical graft
provides early engraftment, it is the UCB graft that usually provides
long-term engraftment. Sebrango and colleagues reported the
results of 55 combined UCB/haploidentical transplants for high-
risk myeloproliferative and lymphoproliferative disorders (60).
The maximum cumulative incidence of neutrophil and platelet
engraftment was 96 and 78% with a median time to recovery of
10 and 32 days, respectively. Full UCB chimerism was achieved
in 50 patients [cumulative incidence 91% (95% CI, 84–99%)]
with a median time of 57 days (range, 11–186 days). Immune
reconstitution analysis showed NK-cell recovery occurred within
3 months, at a time when patients had dual UCB/haploidentical
chimerism. However, B and T cells recovered by 6 months and
1 year, respectively when full UCB chimerism had been attained.
Liu and colleagues transplanted 45 patients using a RIC regimen
with an unrelated UCB graft and CD34+ selected cells from a hap-
loidentical donor (61). The cumulative incidence of neutrophil
engraftment was 95% at day 50 with a median time to recov-
ery of 11 days. The cumulative incidence of platelet engraftment
was 83% at day 100 with a median time to recovery of 19 days.
The median percentage of PB cells of UCB origin was 10, 78, and
95% at day 30, 100, and 180, respectively. Conversely, the median
percentage of PB cells from the haploidentical graft was 86, 22,
and 2% at the corresponding times. The cumulative incidence of
acute and chronic GvHD was 25 and 5%, respectively, with non-
relapse mortality (NRM) at 1 year 38%, relapse 30%, and overall
survival 55%.
IMPROVING DELIVERY AND HOMING OF UCB HSC
To improve HSC engraftment following UCB transplantation,
direct intrabone infusion of cord blood cells is currently being
investigated. In a Phase I/II study, 32 consecutive patients with
acute leukemia received UCB transplants with intrabone infusion
between 2006 and 2008 (62). No complications occurred dur-
ing administration. The median time to neutrophil and platelet
engraftment was 23 days (range, 14–44 days; n= 28) and 36 days
(range, 16–64 days; n= 27), respectively, and all engrafted patients
showed full donor chimerism from day 60 onward. Sixteen patients
were alive and in remission with a median follow-up of 13 months.
Okada and colleagues demonstrated in a Phase I study that intra-
bone infusion of unwashed cord blood following a RIC regimen
was also well tolerated (63). In 10 patients, there were no injec-
tion related complications and the median time to neutrophil
recovery was 17 days. Saglio and colleagues showed that intra-
bone injection was also well tolerated in children (64). In a recent
Eurocord retrospective comparison of single unit intrabone UCB
transplants (n= 87) with double unit intravenous UCB trans-
plants (n= 149), intrabone infusion was associated with improved
neutrophil engraftment by day 30 (76 vs. 62%, P = 0.014) and
improved platelet engraftment by day 180 (74 vs. 64%, P = 0.003).
Intrabone infusion was also associated with a lower incidence of
acute GvHD and had a trend toward improved disease-free sur-
vival (DFS) (65). These results are encouraging and further clinical
trials are currently ongoing to evaluate engraftment kinetics and
immune reconstitution following intrabone infusion (66).
Factors that promote homing of UCB HSC to the BM niche
may also improve engraftment. Stromal-derived factor-1 (SDF-
1) (CXCL12) is produced by BM stromal cells and binds to its
receptor, CXCR4, on the surface of HSC, pre-B lymphocytes,
and T cells. SDF-1 levels are increased following HSCT condi-
tioning and the infused HSC follow the SDF-1 gradient toward
the BM niche. Once engrafted, SDF-1 may also promote HSC
proliferation and survival (67, 68). Many factors increase the sen-
sitivity of CXCR4 on HSC to SDF-1, including complement (C3a),
hyaluronic acid, VCAM-1, fibrinogen, and thrombin. Therefore,
ex vivo priming of UCB HSC with these molecules may pro-
mote homing and engraftment of the HSC (69, 70). Inhibition
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of the membrane bound extracellular peptidase (CD26), which
cleaves SDF-1, also enhances long-term engraftment in UCB
CD34+ cells in NOD/SCID/beta 2 microglobulin null mice (71,
72). Fucosylation of ligands expressed on HSC is also required
for their interaction with selectins expressed in the BM microvas-
culature. In NOD-SCID interleukin-2Rγ (null) mice, Robinson
and colleagues demonstrated that only fucosylated UCB CD34+
were responsible for engraftment and that ex vivo fucosylation
improved UCB engraftment rates (73). All these pre-clinical stud-
ies show encouraging results and, as such, further investigation
is warranted to determine whether these techniques can improve
HSC engraftment in clinical UCB transplantation.
ENHANCED HLA-MATCHING AND DETECTION OF HLA ANTIBODIES
Until recently, CBUs for transplantation were selected using cell
dose (TNC and/or CD34+) and HLA-matching at HLA-A and
-B (antigen) and HLA-DRB1 (allele). However, the importance
of enhanced HLA-matching has now been recognized. In 2011,
Eapen and colleagues retrospectively reviewed the results from 803
single UCB transplants (leukemia/MDS), analyzing the impact of
HLA typing at HLA-A, -B, and -C (intermediate resolution) and
HLA-DRB1 (allelic) (74). Neutrophil recovery (day 28) was infe-
rior in UCB transplants mismatched at three or more HLA-loci
(70, 64, 64, 54, and 44% with zero, one, two, three, and four mis-
matches, respectively). In addition, TRM was higher when CBU
were mismatched at two or more HLA-loci [HR 3.27 (P = 0.006);
HR 3.34 (P = 0.005); HR 3.51 (P = 0.006) for two, three, and four
mismatches]. Compared to fully matched transplants (8/8), CBU
mismatched at HLA-C had higher TRM [HR 3.97 (P = 0.018)].
TRM was also higher in UCB transplants with a single HLA-
mismatch at HLA-A, -B, or -DRBI and mismatched at HLA-C
compared to transplants with a single HLA-mismatch at HLA-A,
-B, or -DRBI but matched for HLA-C [HR 1.70 (P = 0.03)]. Addi-
tional matching for HLA-C was therefore recommended. More
recently, a joint CIBMTR and Eurocord study analyzed the effect
of high resolution (allele) typing at HLA-A, -B, -C, and -DRB1
on the outcomes of 1658 MAC single UCB transplants (75). Neu-
trophil recovery (day 28) was inferior in transplants mismatched
at three or more alleles compared to fully matched CB [odds
ratio (OR) 0.56 (95% CI, 0.36–0.88) P = 0.01; OR 0.55 (95%
CI, 0.34–0.88) P = 0.01; OR 0.45 (95% CI, 0.25–0.82), P = 0.009
for three, four, and five allelic mismatches]. NRM was also asso-
ciated with the degree of HLA-mismatching. Single HLA-allele
mismatches at HLA-A, -C, or -DRB1 had higher NRM [HR 3.05
(1.52–6.14), P = 0.02; HR 3.04 (95% CI, 1.28–7.20), P = 0.01; HR
2.93 (95% CI, 1.38–6.25), P = 0.005, respectively]. Importantly,
CBUs with TNC <3.0× 107/kg were associated with significantly
higher NRM, independent of HLA-matching. Therefore, Eapen
and colleagues proposed that single UCB transplants should have a
minimum TNC dose of 3.0× 107/kg. The best HLA-allele matched
CBU should then be selected. However, units with three or more
HLA-allele mismatches should only be used with caution due to
increased graft failure and higher NRM.
In UCB transplantation, screening for donor specific anti-HLA
antibodies (DSA) should also be considered. In a retrospective
analysis of 386 MAC single UCB transplants performed for hema-
tological malignancies, 89 patients had anti-HLA antibodies, 20
with specificity against the CBU (76). In multivariate analysis,
neutrophil and platelet recovery were significantly worse in these
20 patients compared to the antibody negative group [RR 0.23
(0.09–0.56), P = 0.001; RR 0.31 (95% CI, 0.12–0.81), P = 0.02,
respectively]. Similarly, in 73 double UCB transplants, the pres-
ence of DSA was associated with increased graft failure (5.5 vs.
18.2 vs. 57.1% for none, single, or dual DSA positivity; P = 0.0001)
and a longer median time to neutrophil recovery [29 days (any
DSA) vs. 21 days (no DSA), P = 0.04] (77). More recently, a ret-
rospective Eurocord analysis on the impact of DSA in 294 RIC
UCB transplants was performed. 21% recipients had anti-HLA
antibodies of which 14 (5%) had donor specificity. Day 60 neu-
trophil engraftment (44 vs. 81%, P = 0.006) and 1 year TRM (46
vs. 32%, P = 0.06) were inferior in the presence of DSA (78). In 70
children receiving single UCB transplants, the presence of antibod-
ies to major-histocompatibility-complex Class I-related chain A
antigen (MICA) was also associated with delayed platelet engraft-
ment [HR 4.2 (95% CI, 1.02–17.08), P = 0.04] (79). While not
all studies have found this association between DSA and engraft-
ment, possibly due to use of lower thresholds for DSA detection,
it is recommended that potential recipients be screened for anti-
HLA antibodies before UCB transplantation (79, 80). CBUs for
which the recipient has high levels of DSA should then be avoided.
The full implication of DSA at lower levels remains less clear and
further evaluation is required.
REDUCED-INTENSITY CONDITIONING AND T-REPLETE TRANSPLANTS
The use of RIC regimens in all forms of allogeneic HSCT has
increased over the last decade. RIC regimens are less myeloablative
but provide sufficient immunosuppression to allow donor engraft-
ment. Disease eradication is then dependent upon the donor-
derived T cells recognizing residual tumor as“non-self,”producing
an immune mediated graft-versus-tumor (GvT) response (81).
RIC regimens have less toxicity and lower TRM, therefore allowing
transplantation to be performed in older patients and/or in those
with other significant co-morbidities that would otherwise prevent
HSCT. RIC regimens are now commonly used in both pediatric
and adult UCB transplants (47, 82). However, immune reconstitu-
tion following RIC UCB transplantation has not been extensively
reported. Geyer and colleagues monitored immune subset recov-
ery in 88 consecutive UCB transplants of which 49 had MAC
and 39 had RIC (83). In this series, no significant difference was
observed in T, B, or NK-cell recovery or immunoglobulin recon-
stitution, although the two groups were not evenly matched for
other potential confounding factors, e.g., disease type and status
at transplant.
To improve engraftment and limit GvHD, many UCB trans-
plant regimens also use in vivo T-cell depletion with anti-
thymocyte globulin (ATG). ATG is a polyclonal antibody, pre-
pared in rabbits or horses, raised against thymocyte antigens (84).
Although infused into the recipient pre-transplant, the half-life
of ATG is such that it reduces T cells in both the recipient and
infused grafts, producing profound T-cell depletion and delaying
immune reconstitution. Chiesa and colleagues recently published a
study measuring early immune reconstitution in 30 pediatric UCB
transplants without in vivo T-cell depletion (85). In keeping with
T-depleted transplants, NK-cell recovery was rapid with a median
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time to recovery of 1 month (1–3 months). However, in contrast
to ATG-based protocols, T-cell recovery was faster with a rapid
“thymic-independent” expansion, broader T-cell repertoire with
virus-specific responses, and rapid conversion from naïve to cen-
tral memory phenotype. In particular, CD4+ T-cell recovery was
faster with a median count of 0.6× 109/l at 2 months post-UCB
transplant. Although CD8+ T-cell recovery was delayed, it was still
faster than previously reported for T-depleted UCB transplants.
Similarly, B cell reconstitution was also faster. Twenty-nine of the
30 patients engrafted with the median time to neutrophil engraft-
ment of 22 days (range, 13–38 days) and platelet engraftment of
42 days (range, 17–123 days). The cumulative incidence of grade
II–IV acute GvHD was 50% but chronic GvHD was relatively low
at 14%. In a similar review in adult patients, T-cell reconstitution
was measured in 72 double UCB transplants (52 myeloablative
and 20 non-myeloablative) without ATG (86). In this group, the
median CD4+ T-cell count was 0.27× 109/l at 4 months. Again,
CD4+ T-cell recovery was faster than that seen in similar series of
single and/or double UCB transplants using ATG. Four patients
had graft failure and the median time to neutrophil engraftment
was 23 days (range, 11–43 days) in the myeloablative group and
11 days (range, 7–36 days) in the non-myeloablative group. The
cumulative incidence of acute GvHD at day 100 was 43% (95%
CI, 33–56%) and survival at 1 year was 68% (95% CI, 57–79%).
Therefore, both studies show promising results with potentially
improved immune reconstitution compared to T-depleted UCB
transplants although this has to be balanced against the risk of
GvHD. In addition, as recognized by the authors, the limitations
of comparing results from different retrospective series must be
considered and further studies will be necessary.
INCREASING SPECIFIC CELL POPULATIONS
NK cells
Natural killer cells have an important role in early immunity
against infection and the GvL response following HSCT. NK-cells
expressing the activation receptor, NKG2C, and producing IFNγ
rapidly expand following acute CMV reactivation, reflecting a pri-
mary NK-cell response (87). These cells persist long after viral
clearance and develop a mature phenotype being CD56dim with
high KIR expression and reduced expression of NKG2A. In HLA-
haploidentical transplants, donor-versus-recipient NK-cell allore-
activity also protects against rejection, GvHD, and acute myeloid
leukemia (AML) relapse (88, 89). NK-cell alloreactivity arises from
a mismatch between the inhibitory receptors for self-MHC Class I
molecules on NK cells and MHC Class I antigens on recipient cells
(90). Furthermore, KIR ligand incompatibility in the GvH direc-
tion is an independent predictor of overall survival in AML (89).
In light of these observations, NK-cell immunotherapy has been
used as consolidation treatment in high-risk AML patients and
following leukemic relapse after haploidentical HSCT (91, 92).
In relation to UCB transplantation, isolation and infusion of
NK cells to improve immune recovery and/or treat relapse has
proven difficult due to the low number of cells available in CBUs.
To resolve this issue, several groups have developed ex vivo NK-cell
expansion protocols using UCB (93–96). Beck used Notch receptor
ligand Delta-4 to differentiate and expand UCB CD34+ cells into
NK cells (93). Most were CD16−CD56bright and did not express
inhibitory receptors that bind Class I MHC (NKG2A, KIR) but did
express activating NK receptors (NKG2D) required for cytotoxi-
city against leukemia cells. Tanaka and colleagues expanded NK
cells from unmanipulated UCB cells (1× 106) using Tacrolimus
and low molecular weight heparin without feeder cells (95). This
good manufacturing practice (GMP) compliant method produced
40× 106 NK cells with high levels of stimulatory NK-cell recep-
tors (NKG2C, NKG2D, NKp44). Recently, the same group also
reported that the tyrosine kinase inhibitor, Dasatinib, can enhance
expansion of NK cells from unseparated UCB and, therefore, could
be potentially used to expand NK cells both ex vivo and in vivo
(97). Use of NK cells in UCB transplantation is currently being
investigated in clinical trials (98).
T cells
In view of the prolonged T-cell lymphopenia and high rates of
viral infection observed post-HSCT, there has been much inter-
est in using adoptively transferred viral-specific mature T cells
to improve immune reconstitution and prevent/treat infection.
Pathogen-specific T cells can be expanded ex vivo from small quan-
tities (<2.5%) of GCSF-mobilized PBSCH and have been used in
Phase I/II trials or in selected cases of refractory CMV or EBV
infection (99–102). In vitro techniques are also being developed to
detect, enrich, and produce multiple virus-specific T cells allow-
ing simultaneous adoptive transfer of T cells directed against CMV,
EBV, BKV, and ADV (103, 104). For UCB transplantation, how-
ever, this strategy has proved much more difficult due to the small
number of cells available and because the majority of UCB T cells
are antigen naive. Initial strategies employed ex vivo polyclonal
expansion of all UCB T cells from an aliquot of the CBU using
anti-CD3/CD28 coated Dynabeads and IL-2 (105, 106). Although
expansion and maturation of the T cells was possible, significant
apoptosis of CD4+ T cells occurred and there was a reversal of the
normal CD4:CD8 ratio. Addition of IL-7 to the cultures reduced
apoptosis, increased proliferation to an average fold expansion
of 165, and promoted functional maturation (107). Importantly,
the expanded cells lacked alloreactivity against allogeneic cells but
could be primed against leukemia cells to generate tumor-specific
cytotoxic T cells. Clinical trials of these ex vivo expanded T-cell
products will be necessary. In relation to pathogen-specific T cells,
Park and colleagues first demonstrated that CMV-specific T cells
could be produced from UCB by isolation of T cells, priming with
IL-7 and IL-12 and stimulation with monocytes and dendritic
cells containing CMV antigen (108). More recently, Hanley and
colleagues further developed these techniques to produce GMP-
compliant cytotoxic T cells against CMV, EBV, and ADV (109). In
the first expansion phase, UCB derived T cells are stimulated with
UCB dendritic cells transduced with adenoviral vector containing
the CMV antigen, pp65, in presence of IL-7, IL-12, and IL-15. A
second stimulation is then performed using EBV-transformed B
cells. This method only requires 20% of the CBU and can produce
150× 108 viral specific cells that lyse antigen-pulsed targets and
release effector cytokines in response to antigen stimulation. Phase
I/II trials using the pathogen-specific expanded UCB T cells are
currently in recruitment (110).
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Regulatory T cells
The fundamental principle of the human immune system is to
protect the body from harmful pathogens (“non-self”) while being
unresponsive to self-antigens (“self-tolerance”). In addition to the
passive central mechanisms of tolerance (“positive” and “nega-
tive” selection in the thymus), tolerance is also maintained by
peripheral immune mechanisms. Several cells (“suppressors”) can
suppress autoreactive clones through dominant mechanisms. Of
these, Tregs are arguably the most understood. In 1995, Sakaguchi
and colleagues described a population of CD4+ T cells expressing
the IL-2 receptor alpha chain (CD25) (111). When CD4+CD25−
cells, from BALB/c nu/+mice were transferred into BALB/b nu/nu
mice they induced a widespread autoimmune disease that could
be prevented by co-transfer of donor CD4+CD25+ cells. The
CD4+CD25+ T cells subsequently became known as Tregs and,
in 2001, human CD4+CD25+ Tregs were described (112, 113).
In 2003, the transcription factor forkhead box P3 (Foxp3) was
found to be specifically expressed in Tregs and is thought to be
the master regulator of Treg differentiation and function (114,
115). Scurfy mice have functional mutations in Foxp3 producing a
deficiency of Tregs and a severe multi-systemic autoimmune dis-
order (114, 116, 117). Conversely, ectopic expression of Foxp3 in
murine naïve CD4+ T cells produces suppressive function and
expression of other Treg phenotypic markers, e.g., cytotoxic T
lymphocyte antigen 4 (CTLA-4) (114, 115). FOXP3 is also found
in human Tregs and mutations in FOXP3 cause the IPEX syn-
drome (Immune dysregulation, Polyendocrinopathy, Enteropathy,
X-linked) (118, 119).
Tregs induce peripheral tolerance by inhibiting the proliferation
and cytokine secretion of T, B, NK, NKT, and antigen presenting
cells. Many functional mechanisms have been proposed although
the contribution of each one in vivo remains unclear (120). Cell-
contact independent mechanisms include sequestration of IL-2
and the production of inhibitory cytokines such as IL-10 and IL-
35. As Tregs express high levels of CD25, Tregs may preferentially
absorb IL-2, causing Bim-mediated apoptosis in effector cells due
to relative IL-2 deficiency (121). IL-10 [human cytokine synthesis
inhibitory factor (CSIF)] is an anti-inflammatory cytokine that is
important for maximal Treg function (122). Treg-produced IL-10
suppresses Th17 cells and inhibits IFNγ production by CD4+ T
cells in inflamed tissues (123, 124). Cell-contact dependent mecha-
nisms include CTLA-4, cell surface TGFβ, and granzyme mediated
cell apoptosis (125). CTLA-4 on Tregs down-regulates CD80 and
CD86 expression on APC, preventing activation of effector T cells
through TCR–MHC–APC interactions (126). Activated Tregs also
express GARP-latent TGFβ complex on their cell surface, which
may induce FOXP3 expression in activated T cells in areas of
inflammation, i.e., infectious tolerance (127).
There has been particular interest in Tregs in the setting
of allogeneic HSCT. In murine GvHD models, depletion of
CD25+ Tregs from BM grafts given to lethally irradiated MHC-
mismatched mice significantly increased the severity and mortality
from GvHD (128, 129). Conversely, co-transfer of CD4+CD25+
Tregs with CD4+CD25− effector T cells (1:1) from C57BL/6
mice into MHC-mismatched BALB/c mice prevented the lethal
GvHD seen with the transfer of CD4+CD25− T cells alone (130).
More importantly, co-transfer of isolated CD4+CD25+ Tregs with
CD4+CD25− conventional T cells into an MHC-mismatched
mouse with leukemia were able to prevent GvHD but did not
prevent the GvT response (131). Co-transfer of Tregs specific
for recipient alloantigens were also able to improve immune
reconstitution with faster recovery of total lymphocytes, T, and
B cells (132). In human allogeneic HSCT, reduced numbers of
CD4+CD25high, CD4+FOXP3+, or CD4+CD25highFOXP3+ cells
and reduced FOXP3 mRNA have been observed in the PB of
patients with GvHD (133–138). Furthermore, Magenau and col-
leagues demonstrated that Treg frequency at the start of the GvHD
reduced linearly with increasing GvHD severity, correlated with
the maximum grade of GvHD, and predicted response to treat-
ment (138). In skin and intestinal biopsies, patients with GvHD
also have fewer FOXP3+ cells per CD8+ lymphocyte compared to
patients without GvHD or with non-GvHD inflammation (136,
139). Several studies have also demonstrated that the number of
CD4+FOXP3+ Tregs in PBSCH is an independent predictor of
acute GvHD in MAC transplants (140, 141). A low graft CD3/Treg
ratio in MAC T-replete transplants was also found to be an inde-
pendent predictor of acute GvHD, NRM, and overall survival (142,
143). Of note, UCB grafts contain CD4+CD25+ Tregs with the
proportion of cells inversely correlating with gestational age up
to the levels found in adults (2–5% CD4+ T cells) (144). In con-
trast to adults, the majority of UCB Tregs express naïve markers
(CD45RA/CD38), possess a more undifferentiated gene expres-
sion profile, and do not show initial suppressor activity upon
TCR stimulation (15, 145). However, following antigenic stimula-
tion, these cells upregulate CD25, CTLA-4, and FOXP3, proliferate
with a high capacity, and possess potent suppressive activity with
high IL-10 production (15, 145). These properties may, therefore,
partly explain why UCB transplantation is associated with a lower
incidence of GvHD (14).
Using Tregs in allogeneic HSCT may promote immune recon-
stitution and prevent/treat GvHD while maintaining a GvT
response. In recent years, focus has been on the isolation and
transfer of Tregs around the time of transplantation. Unfortu-
nately, isolation of human Tregs has been hampered by the lack
of Treg-specific surface markers, low Treg frequency, and the
limitations of GMP. Most strategies use GMP-grade magnetic
bead selection of CD25high cells with the depletion of CD8+,
CD19+, or CD127high cells. These Treg-rich products contain
40–60% CD4+CD25++FOXP3+ T cells with in vitro suppres-
sive function (146–148). Using this approach, two clinical trials
of adoptive transfer of Tregs have been performed in humans.
The first was a Phase I study in which patients with a high-risk
of relapse were pre-emptively given up to 5× 106/kg Tregs prior
to donor lymphocyte infusions (DLI) (149). In nine patients,
there were no adverse events related to the Tregs. In the second
study, 28 HLA-haploidentical transplants were given 2–4× 106/kg
isolated Tregs (50% FOXP3+) 4 days prior to receiving CD34+
cells and 0.5–2.0× 106/kg conventional T cells (150). The admin-
istration of Tregs into the lymphopenic environment was to
allow pre-activation and homeostatic expansion of Tregs in vivo
(151). Despite the absence of other immunosuppression, only two
patients developed grade II–IV acute GvHD. In the context of
UCB transplantation, Treg isolation strategies have been problem-
atic due to the lower number of Tregs per CBU. Therefore, ex vivo
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Treg expansion has been necessary. In pre-clinical murine studies,
ex vivo expanded human UCB CD4+CD25+ Tregs can prevent
allogeneic GvHD, reduce Il-17 production, and tip the Treg/Th17
balance in favor of Tregs (152). Initial expansion protocols of adult
Tregs used in vitro CD3/CD28 stimulation of Treg-rich isolations
in the presence of high dose IL-2 (146, 153). However, small num-
bers of contaminating cells rapidly expanded in culture, reducing
the purity of the final product. In addition, repetitive in vitro
stimulation was associated with down-regulation of FOXP3 (154).
Therefore, several refinements to these protocols have been pro-
posed. First, is the combined use of CD25 and CD45RA to isolate
naïve Tregs only and improve Treg purity by depleting contam-
inating effector cells. Naïve Tregs (CD4+CD25+CD45RA+) are
highly proliferative in vitro and have stable phenotype and func-
tion following culture (146). Second, is the addition of Rapamycin
as mTOR inhibition prevents expansion of conventional T cells
whilst allowing expansion of Tregs (155–157). Using a combina-
tion of Rapamycin, IL-15, and TGFβ, Asanuma and colleagues
obtained more than 500-fold expansion of CD4+CD25+ T cells
from UCB and the expanded cells could suppress allogeneic cell
cultures by more than 50% (158). Rapamycin may also convert
conventional T cells into FOXP3+ Tregs. Although the stability of
these cells remains contentious, reports suggest that ex vivo expan-
sion of Tregs in the presence of Rapamycin and all-trans retinoic
acid (ATRA) may be superior to expansion with Rapamycin alone
(159). Only Brunstein and colleagues have reported results using
expanded human Tregs to prevent GvHD (160). Twenty-three
double UCB transplant patients were given expanded Tregs at a
dose of 1–30× 105/kg on day 1, with 13 of these patients receiving
an additional dose of 30× 105/kg on day 15. Tregs were obtained
by CD25 bead isolation from third-party UCB and expanded with
CD3/CD28 beads and IL-2 for 18 days. There were no reported
adverse events from Treg infusion and grade II–IV acute GvHD
was reduced compared to 108 historical controls. These studies
therefore provide encouraging results and are the first tentative
steps toward Treg cellular therapies in UCB transplantation.
While adoptive transfer of human Tregs remains promising,
the ultimate goal is to expand Tregs in vivo and modification of
current GvHD prophylaxis regimens may enable this. Ciclosporin
reduces FOXP3 expression in Tregs, significantly reducing in vitro
and in vivo function of allo-stimulated Tregs and Treg expan-
sion (161–163). Conversely, Rapamycin suppresses conventional
T cells but does not reduce FOXP3 expression or in vivo Treg
function (155–157, 164). In vivo murine studies have shown that
the combination of IL-2 and Rapamycin can selectively expand
Tregs and reduce lethal acute GvHD (165). In Phase II clinical
studies, the combination of Rapamycin and Tacrolimus has also
shown effective prevention of GvHD and lower NRM compared to
historical controls (166, 167). However, there are concerns about
the increased risk of thrombotic microangiopathies. Novel thera-
pies to increase Tregs in vivo are also being investigated. In mice,
in vitro inhibition of DNA methylation using the hypomethylating
agents,Azacitidine or Decitabine,or by knocking out DNA methyl-
transferase 1 (DNMT-1) induced Foxp3 expression in proliferating
naïve CD4+CD25− T cells (168–171). Furthermore, Choi and col-
leagues demonstrated that Decitabine treated naive CD4+CD25−
T cells from B6 mice (60% Foxp3+) were able to protect lethally
irradiated BALB/c mice from GvHD when given T-cell depleted
BM and conventional T cells from the same B6 mice (171). Using
this model, in vivo Azacitidine post-transplant (days 15–21) pre-
vented GvHD without inhibiting the GvL response, increased
FOXP3+ Tregs in the PB, and improved overall survival (171).
Azacitidine has also been shown to increase FOXP3 expression
in human naive T cells although it has been reported that these
cells produce pro-inflammatory cytokines, including IFNγ and
TNFα (169, 172). Therefore, it remains unclear whether demethy-
lation agents will increase functional human Tregs post-HSCT and
whether this will improve immune reconstitution and/or prevent
GvHD. It also remains to be determined whether these agents
can be used following UCB transplantation without effecting
engraftment. Early phase clinical trials are in process.
USE OF MESENCHYMAL STEM CELLS
Mesenchymal stem cells are multipotent undifferentiated stro-
mal cells with capacity to self renew and/or differentiate into
mesenchymal cells including chondrocytes, osteocytes, adipocytes,
cardiomyocytes, and neurons. They are present in PB, BM, UCB,
and non-hematopoietic tissues including fat, muscle, and UC con-
nective tissue, e.g., Wharton’s jelly, although their exact function
in vivo remains unclear. MSC are a heterogeneous population
that lack hematopoietic markers (CD45/CD34/CD14) but express
the antigens SH-3/SH-4 (CD73), Thy-1 (CD90), and Endoglin
(CD105) (173). However, there is considerable phenotypic varia-
tion between MSC obtained from different sources and there is no
universal marker allowing specific isolation of these cells.
In relation to UCB transplantation, MSC have low immuno-
genicity and potent immunosuppressive function that may be
useful for improving engraftment and preventing GvHD. MSC
do not express Class II MHC molecules or co-stimulatory mole-
cules and, thus, do not elicit allo-antigenic responses. They can
also suppress T and NK-cell proliferation, cytokine secretion,
and B cell function (174–176). Possible mechanisms include cell-
contact dependent and independent responses including IL-10,
TGFβ, nitric oxide, and PGE2 and induction of Tregs (174, 177–
179). Pre-clinical murine studies showed that co-transplantation
of MSC with UCB CD34+ cells in NOD/SCID mice improved
engraftment (180–182). In addition, UC MSC supported ex vivo
expansion of UCB HSC in long-term cultures (183). In 2009,
MacMillan and colleagues performed a Phase I/II study of ex
vivo expanded haploidentical BM-derived MSC in pediatric unre-
lated UCB transplants (184). Eight patients received MSC [median
dose 2.1× 106/kg (range, 0.9–5.0)] in addition to UCB [median
TNC 3.1× 107/kg (range, 2.0–12.4)], with three patients receiv-
ing an additional infusion of MSC on day 21. There were no
harmful side effects related to infusion of the MSC. All patients
achieved neutrophil engraftment at a median time 19 days (range,
9–28 days). Six patients achieved platelet engraftment at a median
of 53 days (range, 36–98 days). Rates of engraftment, GvHD, and
survival were comparable to equivalent historical group demon-
strating the safety and feasibility of this approach. In a similar
pilot study, nine patients received MAC followed by UCB trans-
plants with co-infusion of BM-derived MSC and T-depleted HSC
from a third-party donor (185). All patients achieved neutrophil
engraftment at a median of 12 days (range, 10–31 days) with full
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CB chimerism at a median of 51 days (range, 20–186 days). The
maximum cumulative incidence of platelet engraftment was 88%
(95% CI, 70–100%) at a median of 32 days (range, 13–97 days).
However, there was no difference in engraftment rates compared to
a control group of 46 transplants from the same center not receiv-
ing MSC. In addition, they reported no difference in recovery of
lymphocyte populations although their data were not published.
Bernardo and colleagues reported similar findings in 13 pediatric
UCB transplants using paternal MSC with no difference in engraft-
ment or rates of rejection compared to 39 matched historical
controls (186). Recently, a Phase I/II study of UCB transplants with
UC-derived MSC has been performed (187). Five patients received
ex vivo expanded MSC obtained from Wharton’s jelly without any
adverse events. Neutrophil engraftment [median 11 days (range,
7–13 days)] and platelet engraftment [median 32 days (range, 22–
41 days)] were significantly faster than in nine control patients
not receiving MSC. There was no significant difference in total
lymphocyte recovery. However, other studies have demonstrated
that co-infusion of MSC at the time of UCB transplantation
has a negative effect on thymopoiesis and TREC reconstitution,
and was associated with reduced survival (188). Therefore, the
full implications of co-infusion of MSC with UCB transplanta-
tion on engraftment and immune reconstitution require further
clarification.
In murine BMT models, MSC have also reduced GvHD,
although the timing, dose, and frequency appeared critical as
greatest effect was seen when the cells were given into a pro-
inflammatory environment with high levels of IFNγ. MSC were
first administered to a HSCT patient in 2004 when a 9-year-old
boy with refractory GvHD, following a haploidentical transplant,
was given BM-derived MSC with complete resolution of symp-
toms. In 2006, Ringden and colleagues reported a Phase I study
in which eight patients with steroid-refractory grade III–IV acute
GvHD were given MSC at a median dose of 1× 106/kg (range,
0.7–9.0) (189). There were no acute effects related to the infu-
sions and six out of eight patients had complete resolution of
all symptoms. Overall survival was reported to be better than in
a similar group of 16 patients not receiving MSC. In a multi-
center EBMT Phase II study, 55 HSCT patients received ex vivo
expanded BM-derived MSC for steroid-refractory severe acute
GvHD (190). Thirty had a complete response and nine had a
partial response with median time from infusion to CR of 18 days
(range, 3–63 days). Both TRM and overall survival were better
in the complete responders. In a multi-center Phase III study,
244 patients with steroid-refractory grade II–IV acute GvHD
were randomized to receive third-party MSC (eight infusions
of 2× 106/kg). For liver and gastrointestinal GvHD, the overall
response rate at 28 days was higher in the MSC group. However, no
significant difference was found in the rate of durable responses
(>28 days). MSC have also been used in first-line treatment of
GvHD. In a Phase II study, 31 patients with de novo grade II–IV
acute GvHD were randomized to receive third-party MSC at 2 or
8× 106/kg in addition to standard corticosteroid therapy. Com-
plete responses were seen in 77% patients and 16% showed a par-
tial response although there was no difference between the low and
high dose cohorts. To date, few published studies have examined
the use of MSC to treat GvHD following UCB transplantation. In
the study by Gonzalo-Daganzo and colleagues using third-party
MSC and UCB HSC at the time of transplantation, no differ-
ence was observed in acute GvHD (185). However, in this study,
two patients who developed steroid-refractory GvHD were sub-
sequently treated with therapeutic infusions of MSC and both
had complete resolution of symptoms. In Bernardo and colleagues
study, using co-transplantation of UCB and parental MSC, those
patients receiving MSC had less grade III–IV acute GvHD (0 vs.
26%, P = 0.05) although there was no significant difference for
grades II–IV (186). Therefore, the use of MSC to prevent a/or
treat GvHD following UCB transplantation may have a role but
further investigation is required.
USE OF CYTOKINES, GROWTH FACTORS, AND TYROSINE KINASES
Many cytokines and growth hormones involved in normal thymic
function are currently under investigation in pre-clinical studies
to determine whether they improve thymopoiesis and immune
reconstitution post-HSCT. However, to date, few of these have
been specifically tested in the setting of UCB transplantation.
Interleukin-7 is a 25-kDa glycoprotein growth factor produced
by the BM stroma and thymic epithelial cells (TEC) and is impor-
tant for T-cell development. IL-7 binds to its cognate receptor
(IL-7R) on immature thymocytes, promoting their differentiation
and proliferation into immature T lymphocytes. Mutations of the
IL-7 gene or IL-7R produce severe immunodeficiency syndromes
(191). In murine allogeneic BMT models, IL-7 increased thy-
mopoiesis and peripheral expansion of recent thymic emigrants
and mature T cells, as well as increasing B cells, NK cells, NKT
cells, monocytes, and macrophages (192–194). Importantly, in
these studies, GvHD was not exacerbated although GvL was main-
tained (192). However, other similar models have shown increased
GvHD using IL-7 (195). In non-BMT human studies, administra-
tion of rhIL-7 increases CD4+ and CD8+ T cells with a preferential
expansion of naïve T cells and an increased TCR repertoire (196,
197). More recently, Perales and colleagues reported results from
a Phase I trial of rhIL-7 (CYT107) after T-cell depleted allogeneic
HSCT (198). Twelve patients were treated with escalating doses of
rhIL-7 (10–30µg/kg). IL-7 produced an increase in effector mem-
ory T cells with an associated increase in viral specific T cells and
enhanced TCR diversity.
Interleukin-2 is a 15-kDa soluble cytokine produced by acti-
vated T cells and is critical for their differentiation and pro-
liferation into effector cells. It also promotes proliferation and
expansion of B and NK cells and increases cytotoxic activity and
production of effector cytokines. IL-2 binds via its cell surface
receptor containing the IL-2Rα subunit (CD25), IL-2Rβ subunit
(CD122), and the common gamma chain (CD132). As with IL-
7, deficiency in IL-2 or its receptor leads to profound immune
dysregulation with chronic infection and severe autoimmunity
(199). In HSCT, several groups have shown the IL-2 adminis-
tered after chemotherapy or DLI may reduce relapse and increase
responses in refractory disease, possibly through an enhanced GvL
response (200, 201). However, low dose IL-2 produces enhanced
Treg proliferation with increased thymic Treg output while hav-
ing little effect on conventional T cells (202). Therefore, such
strategies may improve T-cell homeostasis post-HSCT, preventing
GvHD and/or thymic damage. Clinical trials using IL-2 in T-cell
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depleted double UCB transplants for refractory AML are currently
in recruitment (203).
Interleukin-15 is a 14- to 15-kDa glycoprotein belonging to
the same family as IL-2 and IL-7. It is expressed by monocytes,
macrophages, and dendritic cells and binds to the IL15Rα sub-
unit, IL-2/15Rβ subunit (CD122), and the common gamma chain
(CD132). Functionally, it causes proliferation of T cells, B cells,
and NK cells and is the primary survival growth factor for NK
cells. In murine BMT models, post-transplant IL-15 administra-
tion increased donor-derived CD8+ T cells, NK cells, and NKT
cells with enhanced NK and T-cell function (204). IL-15 was able to
enhance the GvL effect but also increased GvHD in T-replete BMT.
Sex steroids have important effects on myeloid and lymphoid
recovery following HSCT. The sex steroid hormones (androgen,
estrogen) impair thymic function and cause apoptosis in thymic
stromal cells and developing thymocytes following puberty. Con-
versely, reducing sex steroid levels, either via castration or by
modifying the hypothalamic–pituitary–gonadal axis, increases
thymopoiesis by reducing the rate of apoptosis and increasing
the proliferation of TECs. When a luteinizing hormone releas-
ing hormone agonist (LHRHa) is administered in a continuous
fashion at high doses, LHRH receptors become desensitized and
there is a subsequent reduction in the production of follicle stim-
ulating hormone (FSH) and luteinizing hormone (LH). In turn,
this leads to a reduction in the production of sex steroids (205,
206). Using this approach in a murine BMT model produced
a significant increase in myeloid and lymphoid progenitors and
enhanced thymic reconstitution with increased peripheral T cells
(205). GvHD was not increased but GvL was maintained. Fur-
thermore, combined use of keratinocyte growth factor (KGF) and
LHRHa increased thymopoiesis with enhanced reconstitution on
naïve CD4+ and CD8+ T cells, reduced homeostatic expansion,
and produced a broader T-cell repertoire (207).
Growth hormone (GH) and its mediator insulin-like factor-1
(IGF-1) may also improve thymopoiesis. GH is a 22-kDa protein
produced by the pituitary gland, under the control of the hypothal-
amus via the production of growth hormone releasing hormone
(GHRH) and growth hormone inhibiting hormone (GHIH). It is
also produced by thymocytes and TEC and acts locally with its cor-
responding receptor (GHR) in an autocrine fashion. GH induces
proliferation and cell growth within the thymus and increases
thymic size, cellularity, and TCR repertoire when administered to
GH-deficient mice (208). It also accelerates T-cell and immune
recovery when given in murine T-depleted HSCT (209). Fur-
thermore, GH may also protect against the effects of radiation,
increasing production of HSC and promoting recovery of leuko-
cytes, T, B, and NK cells in murine models (210). IGF-1 is a 7-kDa
protein, which is mainly produced by the liver in response to GH
but is also produced by other cell types in an autocrine fashion.
IGF-1R is expressed on thymocytes, T cells, and TECs and binding
of IGF-1 to its receptor increases the proliferation of thymocytes
and peripheral T cells (211). Administration of IGF-1 in murine
HSCT models also increased in vivo thymic precursor populations,
donor-derived T cells as well as pro-, pre-, and mature B cells, and
myeloid cells (212).
Keratinocyte growth factor is a 28-kDa protein produced by
mesenchymal stromal cells and mature thymocytes. Several groups
have shown that KGF protects mucosal, cutaneous, and epithelial
cells from cytotoxic and irradiation induced injury (213, 214).
In murine BMT models, pre-treatment with KGF protected the
TECs and increased donor-derived thymocytes, peripheral naïve
T cells, and production of IL-7 (215). KGF induces p53 and NF-
kappa pathways in immature TECs, promoting proliferation and
differentiation into mature TECs (216). In a murine UCB trans-
plant model, KGF pre-treatment increased day 35 thymic outputs
with higher T-cell and NKT-cell numbers within the spleen and
increased the proportion of TREC (217). However, in human
clinical trials, although KGF (Palifermin) reduced mucositis, it
has not been shown to have any significant impact on lympho-
cyte reconstitution, GvHD, infectious complications, or overall
survival (218–221).
Finally, other cellular pathways currently being investigated
to improve thymopoiesis post-HSCT are the tyrosine kinases,
Flt-3 and c-Kit, and the tumor suppressor gene, p53. FLT-3-
L, produced in the thymus and expressed on the surface of
perivascular fibroblasts, is upregulated following irradiation and
increases proliferation of Flt-3 positive thymic precursors (222).
Flt-3-L also promotes thymocyte maturation and homeostatic
expansion of peripheral T cells following HSCT (223). Stem
cells factor (SCF) also promotes early thymocyte development
through its receptor tyrosine kinase, c-Kit. Pre-clinical stud-
ies in mice using the tyrosine kinase inhibitor, Sunitinib, sug-
gest that pre-treatment of the recipient may promote improved
donor-derived thymopoiesis by blocking c-Kit in the host’s early
thymic progenitors and, thus, improving accessibility to the
thymic niche (224). p53 is a tumor suppressor gene that acti-
vates DNA repair, arrests cell growth, and induces apoptosis in
response to cell damage. Given the degree of epithelial dam-
age following conditioning chemotherapy and/or irradiation,
it has been proposed that temporary inhibition of p53 may
reduce thymic apoptosis and promote T-cell recovery following
HSCT. In murine HSCT models, Kelly and colleagues demon-
strated that temporary inhibition of p53 using the small molecule
pifithrin-β (PFT-β) prevented damage in TECs (225). More-
over, when combined with KGF, thymic function was improved
post-HSCT with higher numbers of donor-derived naïve CD4+
and CD8+ T cells and enhanced responses against Listeria
monocytogenes.
CONCLUSION
The scientific disciplines of immunology, cellular biology, and
immune regulation following UCB transplantation continue to
rapidly advance and over recent years, our understanding of how
cord blood and neonatal immune cells differ from those found
in adults has become clearer. This information is essential to
improve our understanding of immune reconstitution, and per-
haps, the means to accelerate recovery after UCB transplantation.
Despite our extensive knowledge on the unique biology of CB graft
lymphocytes, many of the characteristics of these cells and their
relevance to immune cell recovery have still not been adequately
evaluated after UCB transplantation. Therefore, more in depth
pre-clinical and clinical studies in these areas are warranted, both
in terms of recovery of normal immune cell function and their
effectiveness in antitumor cell activity.
Frontiers in Immunology | Alloimmunity and Transplantation February 2014 | Volume 5 | Article 68 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
ACKNOWLEDGMENTS
We would like to thank Hugo Soudeyns and the Journal of Leuko-
cyte Biology (Copyright FASEB Office of Publications, Bethesda,
MD, USA) for permission to use Figure 1 (226).
REFERENCES
1. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Dev-
ergie A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia
by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med
(1989) 321(17):1174–8. doi:10.1056/NEJM198910263211707
2. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation:
the first 25 years and beyond. Blood (2013) 122(4):491–8. doi:10.1182/blood-
2013-02-453175
3. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini
R, et al. Outcome of cord-blood transplantation from related and unrelated
donors. Eurocord Transplant Group and the European Blood and Marrow
Transplantation Group. N Engl J Med (1997) 337(6):373–81. doi:10.1056/
NEJM199708073370602
4. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, et al. Com-
parison of outcomes of unrelated bone marrow and umbilical cord blood
transplants in children with acute leukemia. Blood (2001) 97(10):2962–71.
doi:10.1182/blood.V97.10.2962
5. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Trans-
plants of umbilical-cord blood or bone marrow from unrelated donors in
adults with acute leukemia. N Engl J Med (2004) 351(22):2276–85. doi:10.
1056/NEJMoa041469
6. Rocha V, Gluckman E, Eurocord-Netcord R, European B, Marrow Transplant
G. Improving outcomes of cord blood transplantation: HLA matching, cell
dose and other graft- and transplantation-related factors. Br J Haematol (2009)
147(2):262–74. doi:10.1111/j.1365-2141.2009.07883.x
7. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliac-
cio AR, et al. Outcomes among 562 recipients of placental-blood transplants
from unrelated donors. N Engl J Med (1998) 339(22):1565–77. doi:10.1056/
NEJM199811263392201
8. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE,
et al. Outcomes after transplantation of cord blood or bone marrow from unre-
lated donors in adults with leukemia. N Engl J Med (2004) 351(22):2265–75.
doi:10.1056/NEJMoa041276
9. Szabolcs P, Niedzwiecki D. Immune reconstitution after unrelated
cord blood transplantation. Cytotherapy (2007) 9(2):111–22. doi:10.1080/
14653240701231014
10. Rocha V, Broxmeyer HE. New approaches for improving engraftment after
cord blood transplantation. Biol Blood Marrow Transplant (2010) 16(1
Suppl):S126–32. doi:10.1016/j.bbmt.2009.11.001
11. Kaminski BA, Kadereit S, Miller RE, Leahy P, Stein KR, Topa DA, et al.
Reduced expression of NFAT-associated genes in UCB versus adult CD4+
T lymphocytes during primary stimulation. Blood (2003) 102(13):4608–17.
doi:10.1182/blood-2003-05-1732
12. Chen L, Cohen AC, Lewis DB. Impaired allogeneic activation and T-helper 1
differentiation of human cord blood naive CD4 T cells. Biol Blood Marrow
Transplant (2006) 12(2):160–71. doi:10.1016/j.bbmt.2005.10.027
13. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood
and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol
(2011) 79(2):112–26. doi:10.1016/j.critrevonc.2010.07.009
14. Tolar J, Hippen KL, Blazar BR. Immune regulatory cells in umbilical cord
blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol (2009)
147(2):200–6. doi:10.1111/j.1365-2141.2009.07781.x
15. Mayer E, Bannert C, Gruber S, Klunker S, Spittler A, Akdis CA, et al. Cord
blood derived CD4+ CD25(high) T cells become functional regulatory T cells
upon antigen encounter. PLoS One (2012) 7(1):e29355. doi:10.1371/journal.
pone.0029355
16. Drohan L,Harding JJ,Holm B,Cordoba-Tongson E,Dekker CL,Holmes T,et al.
Selective developmental defects of cord blood antigen-presenting cell subsets.
Hum Immunol (2004) 65(11):1356–69. doi:10.1016/j.humimm.2004.09.011
17. Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-
specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of
alloreactivity. Immunol Rev (2006) 212:314–29. doi:10.1111/j.0105-2896.2006.
00422.x
18. Gluckman E,RochaV,Arcese W,Michel G,Sanz G,Chan KW,et al. Factors asso-
ciated with outcomes of unrelated cord blood transplant: guidelines for donor
choice. Exp Hematol (2004) 32(4):397–407. doi:10.1016/j.exphem.2004.01.002
19. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplanta-
tion and expanding options for immunomodulation: an update. Blood (2010)
115(19):3861–8. doi:10.1182/blood-2009-12-234096
20. Petropoulou AD, Rocha V. Risk factors and options to improve engraftment
in unrelated cord blood transplantation. Stem Cells Int (2011) 2011:610514.
doi:10.4061/2011/610514
21. Niehues T, Rocha V, Filipovich AH, Chan KW, Porcher R, Michel G, et al. Fac-
tors affecting lymphocyte subset reconstitution after either related or unrelated
cord blood transplantation in children – a Eurocord analysis. Br J Haematol
(2001) 114(1):42–8. doi:10.1046/j.1365-2141.2001.02900.x
22. Verneris MR, Miller JS. The phenotypic and functional characteristics of umbil-
ical cord blood and peripheral blood natural killer cells. Br J Haematol (2009)
147(2):185–91. doi:10.1111/j.1365-2141.2009.07768.x
23. Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, et al.
The unique profile of cord blood natural killer cells balances incomplete mat-
uration and effective killing function upon activation. Hum Immunol (2012)
73(3):248–57. doi:10.1016/j.humimm.2011.12.015
24. Gaddy J, Broxmeyer HE. Cord blood CD16+56- cells with low lytic activity
are possible precursors of mature natural killer cells. Cell Immunol (1997)
180(2):132–42. doi:10.1006/cimm.1997.1175
25. Ruggeri A, Peffault de Latour R, Carmagnat M, Clave E, Douay C, Larghero J,
et al. Outcomes, infections, and immune reconstitution after double cord blood
transplantation in patients with high-risk hematological diseases. Transpl Infect
Dis (2011) 13(5):456–65. doi:10.1111/j.1399-3062.2011.00632.x
26. Somers JA, Brand A, van Hensbergen Y, Mulder A, Oudshoorn M, Sintnicolaas
K, et al. Double umbilical cord blood transplantation: a study of early engraft-
ment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies.
Biol Blood Marrow Transplant (2013) 19(2):266–73. doi:10.1016/j.bbmt.2012.
09.022
27. Tanaka J, Sugita J, Asanuma S, Arita K, Shono Y, Kikutchi M, et al. Increased
number of CD16(+)CD56(dim) NK cells in peripheral blood mononu-
clear cells after allogeneic cord blood transplantation. Hum Immunol (2009)
70(9):701–5. doi:10.1016/j.humimm.2009.06.002
28. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I,
et al. Delayed immune reconstitution after cord blood transplantation is char-
acterized by impaired thymopoiesis and late memory T-cell skewing. Blood
(2007) 110(13):4543–51. doi:10.1182/blood-2007-05-092130
29. Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD,
et al. Immune recovery in adult patients after myeloablative dual umbilical
cord blood, matched sibling, and matched unrelated donor hematopoietic
cell transplantation. Biol Blood Marrow Transplant (2012) 18(11):1664–76.e1.
doi:10.1016/j.bbmt.2012.06.005
30. Escalon MP, Komanduri KV. Cord blood transplantation: evolving strategies
to improve engraftment and immune reconstitution. Curr Opin Oncol (2010)
22(2):122–9. doi:10.1097/CCO.0b013e328335a56e
31. Hollander GA, Krenger W, Blazar BR. Emerging strategies to boost thymic
function. Curr Opin Pharmacol (2010) 10(4):443–53. doi:10.1016/j.coph.2010.
04.008
32. Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, Busson M, et al. A broad
T-cell repertoire diversity and an efficient thymic function indicate a favorable
long-term immune reconstitution after cord blood stem cell transplantation.
Blood (2002) 99(4):1458–64. doi:10.1182/blood.V99.4.1458
33. Clave E, Lisini D, Douay C, Giorgiani G, Busson M, Zecca M, et al. Thymic
function recovery after unrelated donor cord blood or T-cell depleted HLA-
haploidentical stem cell transplantation correlates with leukemia relapse. Front
Immunol (2013) 4:54. doi:10.3389/fimmu.2013.00054
34. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al.
Transplantation in patients with SCID: mismatched related stem cells or unre-
lated cord blood? Blood (2012) 119(12):2949–55. doi:10.1182/blood-2011-06-
363572
35. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O, et al. Tran-
sitional B cells in humans: characterization and insight from B lymphocyte
reconstitution after hematopoietic stem cell transplantation. Clin Immunol
(2008) 127(1):14–25. doi:10.1016/j.clim.2007.11.013
36. Beck JC, Wagner JE, DeFor TE, Brunstein CG, Schleiss MR, Young JA,
et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord
www.frontiersin.org February 2014 | Volume 5 | Article 68 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
blood transplantation. Biol Blood Marrow Transplant (2010) 16(2):215–22.
doi:10.1016/j.bbmt.2009.09.019
37. Merindol N, Salem Fourati I, Brito RM, Grenier AJ, Charrier E, Cordeiro P,
et al. Reconstitution of protective immune responses against cytomegalovirus
and varicella zoster virus does not require disease development in pedi-
atric recipients of umbilical cord blood transplantation. J Immunol (2012)
189(10):5016–28. doi:10.4049/jimmunol.1201759
38. McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira
SE, et al. Cytomegalovirus-specific T cells are primed early after cord blood
transplant but fail to control virus in vivo. Blood (2013) 121(14):2796–803.
doi:10.1182/blood-2012-09-453720
39. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA,
et al. Marked increased risk of Epstein-Barr virus-related complications with
the addition of antithymocyte globulin to a nonmyeloablative condition-
ing prior to unrelated umbilical cord blood transplantation. Blood (2006)
108(8):2874–80. doi:10.1182/blood-2006-03-011791
40. Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, et al. Inci-
dence and risk factors of EBV reactivation after unrelated cord blood trans-
plantation: a Eurocord and Societe Francaise de Greffe de Moelle-Therapie
Cellulaire collaborative study. Bone Marrow Transplant (2013) 48(2):253–6.
doi:10.1038/bmt.2012.117
41. Vandenbosch K, Ovetchkine P, Champagne MA, Haddad E, Alexandrov L,
Duval M. Varicella-zoster virus disease is more frequent after cord blood
than after bone marrow transplantation. Biol Blood Marrow Transplant (2008)
14(8):867–71. doi:10.1016/j.bbmt.2008.05.006
42. Scheurer ME, Pritchett JC, Amirian ES, Zemke NR, Lusso P, Ljungman P.
HHV-6 encephalitis in umbilical cord blood transplantation: a systematic
review and meta-analysis. Bone Marrow Transplant (2013) 48(4):574–80.
doi:10.1038/bmt.2012.180
43. Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, et al.
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is
the complex result of BK virus infection, preparative regimen intensity and
donor type. Haematologica (2010) 95(7):1183–90. doi:10.3324/haematol.2009.
016758
44. Parody R, Martino R, Rovira M, Vazquez L, Vazquez MJ, de la Camara R,
et al. Severe infections after unrelated donor allogeneic hematopoietic stem
cell transplantation in adults: comparison of cord blood transplantation with
peripheral blood and bone marrow transplantation. Biol Blood Marrow Trans-
plant (2006) 12(7):734–48. doi:10.1016/j.bbmt.2006.03.007
45. Barker JN, Hough RE, van Burik JA, DeFor TE, MacMillan ML, O’Brien MR,
et al. Serious infections after unrelated donor transplantation in 136 children:
impact of stem cell source. Biol Blood Marrow Transplant (2005) 11(5):362–70.
doi:10.1016/j.bbmt.2005.02.004
46. Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after
the transplantation of umbilical-cord blood from two partially matched
unrelated donors. N Engl J Med (2001) 344(24):1870–1. doi:10.1056/
NEJM200106143442417
47. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, et al.
Umbilical cord blood transplantation after nonmyeloablative conditioning:
impact on transplantation outcomes in 110 adults with hematologic disease.
Blood (2007) 110(8):3064–70. doi:10.1182/blood-2007-04-067215
48. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al.
Transplantation of 2 partially HLA-matched umbilical cord blood units to
enhance engraftment in adults with hematologic malignancy. Blood (2005)
105(3):1343–7. doi:10.1182/blood-2004-07-2717
49. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA,
et al. Allogeneic hematopoietic cell transplantation for hematologic malig-
nancy: relative risks and benefits of double umbilical cord blood. Blood (2010)
116(22):4693–9. doi:10.1182/blood-2010-05-285304
50. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH,
et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-
versus-leukemia effect in recipients of 2 units. Blood (2009) 114(19):4293–9.
doi:10.1182/blood-2009-05-220525
51. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M,
et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N
Engl J Med (2012) 367(24):2305–15. doi:10.1056/NEJMoa1207285
52. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. Transplan-
tation of ex vivo expanded cord blood. Biol Blood Marrow Transplant (2002)
8(7):368–76. doi:10.1053/bbmt.2002.v8.pm12171483
53. Levac K, Karanu F, Bhatia M. Identification of growth factor conditions that
reduce ex vivo cord blood progenitor expansion but do not alter human repop-
ulating cell function in vivo. Haematologica (2005) 90(2):166–72.
54. Bordeaux-Rego P, Luzo A, Costa FF, Olalla Saad ST, Crosara-Alberto DP. Both
interleukin-3 and interleukin-6 are necessary for better ex vivo expansion of
CD133+ cells from umbilical cord blood. Stem Cells Dev (2010) 19(3):413–22.
doi:10.1089/scd.2009.0098
55. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al.
Transplantation of ex vivo expanded cord blood cells using the copper chela-
tor tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant
(2008) 41(9):771–8. doi:10.1038/sj.bmt.1705979
56. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein
ID. Notch-mediated expansion of human cord blood progenitor cells capable
of rapid myeloid reconstitution. Nat Med (2010) 16(2):232–6. doi:10.1038/
nm.2080
57. Robinson S, Niu T, de Lima M, Ng J, Yang H, McMannis J, et al. Ex
vivo expansion of umbilical cord blood. Cytotherapy (2005) 7(3):243–50.
doi:10.1080/14653240510027172
58. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al.
Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-
expanded UCB cells: results of a phase 1 trial using the AastromReplicell System.
Blood (2003) 101(12):5061–7. doi:10.1182/blood-2001-12-0290
59. Astori G, Adami V, Mambrini G, Bigi L, Cilli M, Facchini A, et al. Evaluation
of ex vivo expansion and engraftment in NOD-SCID mice of umbilical cord
blood CD34+ cells using the DIDECO “Pluricell System”. Bone Marrow Trans-
plant (2005) 35(11):1101–6. doi:10.1038/sj.bmt.1704964
60. Sebrango A, Vicuna I, de Laiglesia A, Millan I, Bautista G, Martin-Donaire T,
et al. Haematopoietic transplants combining a single unrelated cord blood unit
and mobilized haematopoietic stem cells from an adult HLA-mismatched third
party donor. Comparable results to transplants from HLA-identical related
donors in adults with acute leukaemia and myelodysplastic syndromes. Best
Pract Res Clin Haematol (2010) 23(2):259–74. doi:10.1016/j.beha.2010.05.002
61. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-
intensity conditioning with combined haploidentical and cord blood trans-
plantation results in rapid engraftment, low GVHD, and durable remissions.
Blood (2011) 118(24):6438–45. doi:10.1182/blood-2011-08-372508
62. Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G, et al.
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a
phase I/II study. Lancet Oncol (2008) 9(9):831–9. doi:10.1016/S1470-2045(08)
70180-3
63. Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, et al. Intra-
bone marrow transplantation of unwashed cord blood using reduced-intensity
conditioning treatment: a phase I study. Biol Blood Marrow Transplant (2012)
18(4):633–9. doi:10.1016/j.bbmt.2011.08.010
64. Saglio F, Berger M, Vassallo E, Nesi F, Gunetti M, Fazio L, et al. Intrabone cord
blood hematopoietic stem cell transplantation in a subset of very high-risk
pediatric patients: a safety and feasibility pilot study. J Pediatr Hematol Oncol
(2012) 34(5):359–63. doi:10.1097/MPH.0b013e318241fb67
65. Rocha V, Labopin M, Ruggeri A, Podesta M, Gallamini A, Bonifazi F, et al.
Unrelated cord blood transplantation: outcomes after single-unit intrabone
injection compared with double-unit intravenous injection in patients with
hematological malignancies. Transplantation (2013) 95(10):1284–91. doi:10.
1097/TP.0b013e318288ca4d
66. Bittencourt H. Intrabone Infusion of Umbilical Cord Blood Stem Cells
(NCT01711788) ClinicalTrials.gov. Bethesda (MD): National Library of Med-
icine (US) (2013) [updated 2013 Oct 31; cited 2013 Nov 01]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01711788
67. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, et al. Chemokine
SDF-1 enhances circulating CD34(+) cell proliferation in synergy with
cytokines: possible role in progenitor survival. Blood (2000) 95(3):756–68.
68. Broxmeyer HE, Kohli L, Kim CH, Lee Y, Mantel C, Cooper S, et al. Stro-
mal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of
myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances
engraftment of competitive, repopulating stem cells. J Leukoc Biol (2003)
73(5):630–8. doi:10.1189/jlb.1002495
69. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, et al. CD44
and hyaluronic acid cooperate with SDF-1 in the trafficking of human
CD34+ stem/progenitor cells to bone marrow. Blood (2004) 103(8):2981–9.
doi:10.1182/blood-2003-10-3611
Frontiers in Immunology | Alloimmunity and Transplantation February 2014 | Volume 5 | Article 68 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
70. Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord
blood stem cell engraftment in adult patients. Expert Rev Hematol (2010)
3(3):273–83. doi:10.1586/ehm.10.24
71. Christopherson KW II, Paganessi LA, Napier S, Porecha NK. CD26 inhibi-
tion on CD34+ or lineage- human umbilical cord blood donor hematopoi-
etic stem cells/hematopoietic progenitor cells improves long-term engraft-
ment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev (2007)
16(3):355–60. doi:10.1089/scd.2007.9996
72. Jimenez A, Fung HC, Christopherson KW II. Cellular therapies supplement:
strategies for improving transplant efficiency in the context of cellular ther-
apeutics. Transfusion (2011) 51(Suppl 4):125S–37S. doi:10.1111/j.1537-2995.
2011.03375.x
73. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, et al.
Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID
IL-2Rgamma(null) mice. Exp Hematol (2012) 40(6):445–56. doi:10.1016/j.
exphem.2012.01.015
74. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Effect
of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes
after umbilical-cord blood transplantation for leukaemia and myelodysplas-
tic syndrome: a retrospective analysis. Lancet Oncol (2011) 12(13):1214–21.
doi:10.1016/S1470-2045(11)70260-1
75. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of
allele-level HLA matching on outcomes after myeloablative single unit umbil-
ical cord blood transplantation for hematologic malignancy. Blood (2014)
123(1):133–40. doi:10.1182/blood-2013-05-506253
76. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of
anti-HLA antibodies on unrelated cord blood transplantations. Blood (2010)
116(15):2839–46. doi:10.1182/blood-2009-10-249219
77. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B,Armand P, et al. Donor-specific
anti-HLA antibodies predict outcome in double umbilical cord blood trans-
plantation. Blood (2011) 118(25):6691–7. doi:10.1182/blood-2011-05-355263
78. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of
donor-specific anti-HLA antibodies on graft failure and survival after reduced
intensity conditioning-unrelated cord blood transplantation: a Eurocord, Soci-
ete Francophone d’Histocompatibilite et d’Immunogenetique (SFHI) and
Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
analysis. Haematologica (2013) 98(7):1154–60. doi:10.3324/haematol.2012.
077685
79. Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F,
Chalandon Y, et al. The clinical relevance of pre-formed anti-HLA and anti-
MICA antibodies after cord blood transplantation in children. PLoS One (2013)
8(8):e72141. doi:10.1371/journal.pone.0072141
80. Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA
antibodies in double umbilical cord blood transplantation. Biol Blood Marrow
Transplant (2011) 17(11):1704–8. doi:10.1016/j.bbmt.2011.04.013
81. Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning
for allogeneic hematopoietic cell transplantation: current perspectives. Biol
Blood Marrow Transplant (2007) 13(1 Suppl 1):87–97. doi:10.1016/j.bbmt.
2006.10.015
82. Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van
Heeckeren W, et al. Prospective study of one- vs two-unit umbilical cord
blood transplantation following reduced intensity conditioning in adults with
hematological malignancies. Bone Marrow Transplant (2012) 47(7):924–33.
doi:10.1038/bmt.2011.195
83. Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, et al.
A comparison of immune reconstitution and graft-versus-host disease fol-
lowing myeloablative conditioning versus reduced toxicity conditioning and
umbilical cord blood transplantation in paediatric recipients. Br J Haematol
(2011) 155(2):218–34. doi:10.1111/j.1365-2141.2011.08822.x
84. Simpson D. T-cell depleting antibodies: new hope for induction of allograft
tolerance in bone marrow transplantation? BioDrugs (2003) 17(3):147–54.
doi:10.2165/00063030-200317030-00001
85. Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJ, Zhan H, et al. Omis-
sion of in vivo T-cell depletion promotes rapid expansion of naive CD4+
cord blood lymphocytes and restores adaptive immunity within 2 months
after unrelated cord blood transplant. Br J Haematol (2012) 156(5):656–66.
doi:10.1111/j.1365-2141.2011.08994.x
86. Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, et al. Seri-
ous infection risk and immune recovery after double-unit cord blood
transplantation without antithymocyte globulin. Biol Blood Marrow Transplant
(2011) 17(10):1460–71. doi:10.1016/j.bbmt.2011.02.001
87. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, et al. Human
cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are trans-
plantable and expand in vivo in response to recipient CMV antigen. J Immunol
(2012) 189(10):5082–8. doi:10.4049/jimmunol.1201964
88. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A,
et al. Effectiveness of donor natural killer cell alloreactivity in mismatched
hematopoietic transplants. Science (2002) 295(5562):2097–100. doi:10.1126/
science.1068440
89. Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK
cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood
Cells Mol Dis (2008) 40(1):84–90. doi:10.1016/j.bcmd.2007.06.029
90. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Nat-
ural killer cell alloreactivity and haplo-identical hematopoietic transplantation.
Cytotherapy (2006) 8(6):554–8. doi:10.1080/14653240601078721
91. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, et al. Generation
of donor natural killer cells from CD34(+) progenitor cells and subse-
quent infusion after HLA-mismatched allogeneic hematopoietic cell trans-
plantation: a feasibility study. Bone Marrow Transplant (2010) 45(6):1038–46.
doi:10.1038/bmt.2009.304
92. Nguyen S, Beziat V, Norol F, Uzunov M, Trebeden-Negre H, Azar N, et al.
Infusion of allogeneic natural killer cells in a patient with acute myeloid
leukemia in relapse after haploidentical hematopoietic stem cell transplanta-
tion. Transfusion (2011) 51(8):1769–78. doi:10.1111/j.1537-2995.2010.03058.
x
93. Beck RC. Production of cytotoxic, KIR-negative NK cells from CD34+ cord
blood cells with the use of Notch signaling. Transfusion (2011) 51(Suppl
4):145S–52S. doi:10.1111/j.1537-2995.2011.03377.x
94. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T,
et al. Clinical-grade generation of active NK cells from cord blood hematopoi-
etic progenitor cells for immunotherapy using a closed-system culture process.
PLoS One (2011) 6(6):e20740. doi:10.1371/journal.pone.0020740
95. Tanaka J, Sugita J, Shiratori S, Shigematu A, Asanuma S, Fujimoto K, et al.
Expansion of NK cells from cord blood with antileukemic activity using GMP-
compliant substances without feeder cells. Leukemia (2012) 26(5):1149–52.
doi:10.1038/leu.2011.345
96. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, et al. Optimized proto-
cols for generation of cord blood-derived cytokine-induced killer/natural killer
cells. Anticancer Res (2010) 30(9):3493–9.
97. Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M. Dasatinib enhances
the expansion of CD56+CD3- NK cells from cord blood. Blood (2012)
119(25):6175–6. doi:10.1182/blood-2012-03-416800
98. Hosing C. Natural Killer (NK) Cells in Cord Blood Transplantation
(NCT01619761) ClinicalTrials.gov. Bethesda (MD): National Library of Medi-
cine (US) (2013) [cited 2013 Nov 01]. Available from: http://clinicaltrials.gov/
ct2/show/NCT01619761
99. Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A, et al. Adop-
tive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem
cell transplant patients with refractory CMV infections. J Immunother (2012)
35(3):293–8. doi:10.1097/CJI.0b013e31824300a2
100. Meij P, Jedema I, van der Hoorn MA, Bongaerts R, Cox L, Wafelman AR, et al.
Generation and administration of HA-1-specific T-cell lines for the treatment
of patients with relapsed leukemia after allogeneic stem cell transplantation: a
pilot study. Haematologica (2012) 97(8):1205–8. doi:10.3324/haematol.2011.
053371
101. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, et al. Donor-derived
CMV-specific T cells reduce the requirement for CMV-directed pharmacother-
apy after allogeneic stem cell transplantation. Blood (2013) 121(18):3745–58.
doi:10.1182/blood-2012-08-448977
102. Clancy LE, Blyth E, Simms RM, Micklethwaite KP, Ma CK, Burgess JS, et al.
Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded
from granulocyte colony-stimulating factor-mobilized hemopoietic progeni-
tor cell products ex vivo and safely transferred to stem cell transplantation
recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant
(2013) 19(5):725–34. doi:10.1016/j.bbmt.2013.01.021
103. Geyeregger R, Freimuller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J,
et al. Short-term in-vitro expansion improves monitoring and allows afford-
able generation of virus-specific T-cells against several viruses for a broad
www.frontiersin.org February 2014 | Volume 5 | Article 68 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
clinical application. PLoS One (2013) 8(4):e59592. doi:10.1371/journal.pone.
0059592
104. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, et al. Adoptive
transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treat-
ment for EBV reactivation and lymphoproliferative disorders after allogeneic
stem-cell transplantation. J Clin Oncol (2013) 31(1):39–48. doi:10.1200/JCO.
2011.39.8495
105. Mazur MA, Davis CC, Szabolcs P. Ex vivo expansion and Th1/Tc1 maturation
of umbilical cord blood T cells by CD3/CD28 costimulation. Biol Blood Marrow
Transplant (2008) 14(10):1190–6. doi:10.1016/j.bbmt.2008.07.016
106. Okas M, Gertow J, Uzunel M, Karlsson H, Westgren M, Karre K, et al. Clin-
ical expansion of cord blood-derived T cells for use as donor lymphocyte
infusion after cord blood transplantation. J Immunother (2010) 33(1):96–105.
doi:10.1097/CJI.0b013e3181b291a4
107. Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P. Interleukin-7 per-
mits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T
cells: a critical step toward adoptive immunotherapy after cord blood trans-
plantation. Cancer Res (2010) 70(13):5249–58. doi:10.1158/0008-5472.CAN-
09-2860
108. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of
cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lympho-
cytes. Blood (2006) 108(5):1770–3. doi:10.1182/blood-2005-10-006536
109. Hanley PJ, Lam S, Shpall EJ, Bollard CM. Expanding cytotoxic T lymphocytes
from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and
adenovirus. J Vis Exp (2012) (63):e3627. doi:10.3791/3627
110. Bollard C. Safety, Toxicity and MTD of One Intravenous IV Injection of Donor
CTLs Specific for CMV and Adenovirus (ACT-CAT) (NCT00880789) Clinical-
Trials.gov. Bethesda (MD): National Library of Medicine (US) (2013) [updated
2013 Oct 31; cited 2013 Nov 01]. Available from: http://clinicaltrials.gov/ct2/
show/NCT00880789
111. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains
(CD25). Breakdown of a single mechanism of self-tolerance causes various
autoimmune diseases. J Immunol (1995) 155(3):1151–64.
112. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp
Med (2001) 193(11):F41–6. doi:10.1084/jem.193.11.F41
113. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymo-
cytes and peripheral T cells have immune suppressive activity in vitro. Eur
J Immunol (2001) 31(4):1247–54. doi:10.1002/1521-4141(200104)31:4<1247:
:AID-IMMU1247>3.0.CO;2-M
114. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and
function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4(4):330–6.
doi:10.1038/ni904
115. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell develop-
ment by the transcription factor Foxp3. Science (2003) 299(5609):1057–61.
doi:10.1126/science.1079490
116. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al.
Disruption of a new forkhead/winged-helix protein, scurfin, results in the
fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet (2001)
27(1):68–73. doi:10.1038/83784
117. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, et al. Selective
depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med
(2007) 204(1):57–63. doi:10.1084/jem.20061852
118. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al.
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syn-
drome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 27(1):20–1.
doi:10.1038/83713
119. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling
KL, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ reg-
ulatory T cells at the single-cell level. Eur J Immunol (2005) 35(6):1681–91.
doi:10.1002/eji.200526189
120. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regula-
tory T cells: how do they suppress immune responses? Int Immunol (2009)
21(10):1105–11. doi:10.1093/intimm/dxp095
121. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+
Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis
of effector CD4+ T cells. Nat Immunol (2007) 8(12):1353–62. doi:10.1038/
ni1536
122. Collison LW, Pillai MR, Chaturvedi V,Vignali DA. Regulatory T cell suppression
is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent
manner. J Immunol (2009) 182(10):6121–8. doi:10.4049/jimmunol.0803646
123. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM,
et al. Interleukin-10 signaling in regulatory T cells is required for suppres-
sion of Th17 cell-mediated inflammation. Immunity (2011) 34(4):566–78.
doi:10.1016/j.immuni.2011.03.018
124. Sojka DK, Fowell DJ. Regulatory T cells inhibit acute IFN-gamma synthe-
sis without blocking T-helper cell type 1 (Th1) differentiation via a com-
partmentalized requirement for IL-10. Proc Natl Acad Sci U S A (2011)
108(45):18336–41. doi:10.1073/pnas.1110566108
125. Shevach EM, Tran DQ, Davidson TS, Andersson J. The critical contribution of
TGF-beta to the induction of Foxp3 expression and regulatory T cell function.
Eur J Immunol (2008) 38(4):915–7. doi:10.1002/eji.200738111
126. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cut-
ting edge: human CD4+CD25+ T cells restrain the maturation and antigen-
presenting function of dendritic cells. J Immunol (2004) 172(8):4676–80.
127. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP
(LRRC32) is essential for the surface expression of latent TGF-beta on platelets
and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A (2009)
106(32):13445–50. doi:10.1073/pnas.0901944106
128. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of
donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant
(2002) 8(10):525–35. doi:10.1053/bbmt.2002.v8.pm12434947
129. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded
CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease
lethality. Blood (2002) 99(10):3493–9. doi:10.1182/blood.V99.10.3493
130. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type
CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host
disease after allogeneic bone marrow transplantation. J Exp Med (2002)
196(3):389–99. doi:10.1084/jem.20020399
131. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al.
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while
inhibiting graft-versus-host disease after bone marrow transplantation. Nat
Med (2003) 9(9):1144–50. doi:10.1038/nm915
132. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al.
Recipient-type specific CD4+CD25+ regulatory T cells favor immune recon-
stitution and control graft-versus-host disease while maintaining graft-versus-
leukemia. J Clin Invest (2003) 112(11):1688–96. doi:10.1172/JCI17702
133. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Associa-
tion of Foxp3 regulatory gene expression with graft-versus-host disease. Blood
(2004) 104(7):2187–93. doi:10.1182/blood-2004-03-1040
134. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced
frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic
graft-versus-host disease. Blood (2005) 106(8):2903–11. doi:10.1182/blood-
2005-03-1257
135. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, et al.
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with
a low risk of GVHD following HLA-matched allogeneic SCT. Blood (2006)
108(4):1291–7. doi:10.1182/blood-2006-02-003996
136. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal
FOXP3+ regulatory T cells are numerically deficient in acute and chronic
GvHD. Blood (2006) 107(4):1717–23. doi:10.1182/blood-2005-06-2529
137. Schneider M, Munder M, Karakhanova S, Ho AD, Goerner M. The initial phase
of graft-versus-host disease is associated with a decrease of CD4+CD25+ reg-
ulatory T cells in the peripheral blood of patients after allogeneic stem cell
transplantation. Clin Lab Haematol (2006) 28(6):382–90. doi:10.1111/j.1365-
2257.2006.00825.x
138. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, et al. Fre-
quency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and
prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood
Marrow Transplant (2010) 16(7):907–14. doi:10.1016/j.bbmt.2010.02.026
139. Fondi C, Nozzoli C, Benemei S, Baroni G, Saccardi R, Guidi S, et al. Increase
in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower
disease severity and treatment response. Biol Blood Marrow Transplant (2009)
15(8):938–47. doi:10.1016/j.bbmt.2009.04.009
140. Wolf D, Wolf AM, Fong D, Rumpold H, Strasak A, Clausen J, et al. Regula-
tory T-cells in the graft and the risk of acute graft-versus-host disease after
Frontiers in Immunology | Alloimmunity and Transplantation February 2014 | Volume 5 | Article 68 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
allogeneic stem cell transplantation. Transplantation (2007) 83(8):1107–13.
doi:10.1097/01.tp.0000260140.04815.77
141. Pabst C, Schirutschke H, Ehninger G, Bornhauser M, Platzbecker U. The graft
content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+
predicts the risk of acute graft versus host disease after transplantation of allo-
geneic peripheral blood stem cells from unrelated donors. Clin Cancer Res
(2007) 13(10):2916–22. doi:10.1158/1078-0432.CCR-06-2602
142. Pastore D, Delia M, Mestice A, Carluccio P, Perrone T, Gaudio F, et al.
CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease
and immunologic recovery after allogeneic peripheral blood stem cell trans-
plantation. Biol Blood Marrow Transplant (2012) 18(6):887–93. doi:10.1016/j.
bbmt.2011.10.039
143. Delia M, Pastore D, Mestice A, Carluccio P, Perrone T, Gaudio F, et al. Out-
come of allogeneic peripheral blood stem cell transplantation by donor graft
CD3+/Tregs ratio: a single-center experience. Biol Blood Marrow Transplant
(2013) 19(3):495–9. doi:10.1016/j.bbmt.2012.11.015
144. Takahata Y, Nomura A, Takada H, Ohga S, Furuno K, Hikino S, et al.
CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with
naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. Exp
Hematol (2004) 32(7):622–9. doi:10.1016/j.exphem.2004.03.012
145. Torelli GF, Maggio R, Peragine N, Chiaretti S, De Propris MS, Lucarelli B, et al.
Functional analysis and gene expression profile of umbilical cord blood reg-
ulatory T cells. Ann Hematol (2012) 91(2):155–61. doi:10.1007/s00277-011-
1288-y
146. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, et al. Only the
CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous
regulatory T-cell lines upon in vitro expansion. Blood (2006) 108(13):4260–7.
doi:10.1182/blood-2006-06-027409
147. Wichlan DG, Roddam PL, Eldridge P, Handgretinger R, Riberdy JM. Effi-
cient and reproducible large-scale isolation of human CD4+ CD25+ reg-
ulatory T cells with potent suppressor activity. J Immunol Methods (2006)
315(1–2):27–36. doi:10.1016/j.jim.2006.06.014
148. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I.
Clinical grade Treg: GMP isolation, improvement of purity by CD127 deple-
tion, Treg expansion, and Treg cryopreservation. PLoS One (2008) 3(9):e3161.
doi:10.1371/journal.pone.0003161
149. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strate-
gies and first clinical experiences. Curr Opin Immunol (2011) 23(5):679–84.
doi:10.1016/j.coi.2011.06.006
150. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs
prevent GVHD and promote immune reconstitution in HLA-haploidentical
transplantation. Blood (2011) 117(14):3921–8. doi:10.1182/blood-2010-10-
311894
151. Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH, et al.
In vivo dynamics of regulatory T-cell trafficking and survival predict effective
strategies to control graft-versus-host disease following allogeneic transplan-
tation. Blood (2007) 109(6):2649–56. doi:10.1182/blood-2006-08-044529
152. Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, et al. Amelioration of acute graft-
versus-host disease by adoptive transfer of ex vivo expanded human cord blood
CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with
the polarization of Treg/Th17 balance in a mouse model. Transfusion (2012)
52(6):1333–47. doi:10.1111/j.1537-2995.2011.03448.x
153. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, et al. In vitro expanded
human CD4+CD25+ regulatory T cells suppress effector T cell proliferation.
Clin Immunol (2005) 115(1):3–9. doi:10.1016/j.clim.2005.02.017
154. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, et al. Loss
of FOXP3 expression in natural human CD4+CD25+ regulatory T cells
upon repetitive in vitro stimulation. Eur J Immunol (2009) 39(4):1088–97.
doi:10.1002/eji.200838904
155. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands
CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 105(12):4743–8. doi:10.
1182/blood-2004-10-3932
156. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selec-
tive survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T
cells cultured with rapamycin. J Immunol (2007) 178(1):320–9.
157. Strauss L, Czystowska M, Szajnik M, Mandapathil M,Whiteside TL. Differential
responses of human regulatory T cells (Treg) and effector T cells to rapamycin.
PLoS One (2009) 4(6):e5994. doi:10.1371/journal.pone.0005994
158. Asanuma S, Tanaka J, Sugita J, Kosugi M, Shiratori S, Wakasa K, et al. Expan-
sion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells
using the common gamma-chain cytokines (IL-2 and IL-15) and rapamycin.
Ann Hematol (2011) 90(6):617–24. doi:10.1007/s00277-010-1121-z
159. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL.
Retinoic acid and rapamycin differentially affect and synergistically promote
the ex vivo expansion of natural human T regulatory cells. PLoS One (2011)
6(1):e15868. doi:10.1371/journal.pone.0015868
160. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J,
et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted
with umbilical cord blood: safety profile and detection kinetics. Blood (2011)
117(3):1061–70. doi:10.1182/blood-2010-07-293795
161. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and
not cyclosporin A, preserves the highly suppressive CD27+ subset of human
CD4+CD25+ regulatory T cells. Blood (2006) 107(3):1018–23. doi:10.1182/
blood-2005-07-3032
162. Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB,
et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral
preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant (2007)
39(9):537–45. doi:10.1038/sj.bmt.1705628
163. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of
CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-
2 production. Blood (2006) 108(1):390–9. doi:10.1182/blood-2006-01-0329
164. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory
T cells: implications for the choice of immunosuppressive drug therapy. Cell
Cycle (2008) 7(4):458–62. doi:10.4161/cc.7.4.5454
165. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin
and IL-2 reduce lethal acute graft-versus-host disease associated with increased
expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood (2011)
118(8):2342–50. doi:10.1182/blood-2010-10-313684
166. Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, et al. Compari-
son of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and
mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophy-
laxis after reduced-intensity conditioning allogeneic peripheral blood stem
cell transplantation. Biol Blood Marrow Transplant (2009) 15(7):844–50.
doi:10.1016/j.bbmt.2009.03.017
167. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, et al.
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling
donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Blood (2010) 115(5):1098–105. doi:10.1182/blood-2009-03-207563
168. Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, et al.
DNA methylation controls Foxp3 gene expression. Eur J Immunol (2008)
38(6):1654–63. doi:10.1002/eji.200838105
169. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression.
Blood (2009) 114(18):3727–35. doi:10.1182/blood-2009-05-219584
170. Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB, et al. Use of epigenetic
modification to induce FOXP3 expression in naive T cells. Transplant Proc
(2009) 41(5):1848–54. doi:10.1016/j.transproceed.2009.02.101
171. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo
administration of hypomethylating agents mitigate graft-versus-host dis-
ease without sacrificing graft-versus-leukemia. Blood (2010) 116(1):129–39.
doi:10.1182/blood-2009-12-257253
172. Nagar M, Vernitsky H, Cohen Y, Dominissini D, Berkun Y, Rechavi G, et al. Epi-
genetic inheritance of DNA methylation limits activation-induced expression
of FOXP3 in conventional human CD25-CD4+ T cells. Int Immunol (2008)
20(8):1041–55. doi:10.1093/intimm/dxn062
173. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause
D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement. Cytotherapy
(2006) 8(4):315–7. doi:10.1080/14653240600855905
174. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal
stem cells. Eur J Immunol (2006) 36(10):2566–73. doi:10.1002/eji.200636416
175. Giuliani M, Oudrhiri N, Noman ZM,Vernochet A, Chouaib S,Azzarone B, et al.
Human mesenchymal stem cells derived from induced pluripotent stem cells
down-regulate NK-cell cytolytic machinery. Blood (2011) 118(12):3254–62.
doi:10.1182/blood-2010-12-325324
176. Tobin LM, Healy ME, English K, Mahon BP. Human mesenchymal stem
cells suppress donor CD4(+) T cell proliferation and reduce pathology in a
www.frontiersin.org February 2014 | Volume 5 | Article 68 | 17
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol
(2013) 172(2):333–48. doi:10.1111/cei.12056
177. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Iden-
tification of IL-10 and TGF-beta transcripts involved in the inhibition of T-
lymphocyte proliferation during cell contact with human mesenchymal stem
cells. Gene Expr (2007) 13(4–5):217–26. doi:10.3727/000000006780666957
178. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leuko-
cyte antigen-G5 secretion by human mesenchymal stem cells is required
to suppress T lymphocyte and natural killer function and to induce
CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2008) 26(1):212–22.
doi:10.1634/stemcells.2007-0554
179. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe
WE, et al. Multipotent stromal cells induce human regulatory T cells through
a novel pathway involving skewing of monocytes toward anti-inflammatory
macrophages. Stem Cells (2013) 31(9):1980–91. doi:10.1002/stem.1432
180. Noort WA, Kruisselbrink AB, in’t Anker PS, Kruger M, van Bezooijen RL, de
Paus RA, et al. Mesenchymal stem cells promote engraftment of human umbili-
cal cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol (2002)
30(8):870–8. doi:10.1016/S0301-472X(02)00820-2
181. Kim DW, Chung YJ, Kim TG, Kim YL, Oh IH. Cotransplantation of third-
party mesenchymal stromal cells can alleviate single-donor predominance
and increase engraftment from double cord transplantation. Blood (2004)
103(5):1941–8. doi:10.1182/blood-2003-05-1601
182. Fei XM, Wu YJ, Chang Z, Miao KR, Tang YH, Zhou XY, et al. Co-culture of cord
blood CD34(+) cells with human BM mesenchymal stromal cells enhances
short-term engraftment of cord blood cells in NOD/SCID mice. Cytotherapy
(2007) 9(4):338–47. doi:10.1080/14653240701291638
183. Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, et al. Mes-
enchymal stem cells from the Wharton’s jelly of umbilical cord segments pro-
vide stromal support for the maintenance of cord blood hematopoietic stem
cells during long-term ex vivo culture. Transfusion (2008) 48(12):2638–44.
doi:10.1111/j.1537-2995.2008.01926.x
184. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-
vivo culture-expanded parental haploidentical mesenchymal stem cells to pro-
mote engraftment in pediatric recipients of unrelated donor umbilical cord
blood: results of a phase I-II clinical trial. Bone Marrow Transplant (2009)
43(6):447–54. doi:10.1038/bmt.2008.348
185. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Rico MA, Bautista G,
Krsnik I, et al. Results of a pilot study on the use of third-party donor mes-
enchymal stromal cells in cord blood transplantation in adults. Cytotherapy
(2009) 11(3):278–88. doi:10.1080/14653240902807018
186. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, et al.
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening
acute GVHD, but does not reduce the risk of graft failure in pediatric patients
undergoing allogeneic umbilical cord blood transplantation. Bone Marrow
Transplant (2011) 46(2):200–7. doi:10.1038/bmt.2010.87
187. Wu KH, Sheu JN, Wu HP, Tsai C, Sieber M, Peng CT, et al. Cotransplanta-
tion of umbilical cord-derived mesenchymal stem cells promote hematopoi-
etic engraftment in cord blood transplantation: a pilot study. Transplantation
(2013) 95(5):773–7. doi:10.1097/TP.0b013e31827a93dd
188. Uhlin M, Sairafi D, Berglund S, Thunberg S, Gertow J, Ringden O, et al. Mes-
enchymal stem cells inhibit thymic reconstitution after allogeneic cord blood
transplantation. Stem Cells Dev (2012) 21(9):1409–17. doi:10.1089/scd.2011.
0310
189. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies
H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-
versus-host disease. Transplantation (2006) 81(10):1390–7. doi:10.1097/01.tp.
0000214462.63943.14
190. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mes-
enchymal stem cells for treatment of steroid-resistant, severe, acute graft-
versus-host disease: a phase II study. Lancet (2008) 371(9624):1579–86.
doi:10.1016/S0140-6736(08)60690-X
191. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression
in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998)
20(4):394–7. doi:10.1038/3877
192. Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, et al.
Administration of interleukin-7 after allogeneic bone marrow transplantation
improves immune reconstitution without aggravating graft-versus-host dis-
ease. Blood (2001) 98(7):2256–65. doi:10.1182/blood.V98.7.2256
193. Broers AE, Posthumus-van Sluijs SJ, Spits H, van der Holt B, Lowenberg B,
Braakman E, et al. Interleukin-7 improves T-cell recovery after experimen-
tal T-cell-depleted bone marrow transplantation in T-cell-deficient mice by
strong expansion of recent thymic emigrants. Blood (2003) 102(4):1534–40.
doi:10.1182/blood-2002-11-3349
194. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S,
et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in nor-
mal and SIV-infected nonhuman primates. Blood (2003) 101(6):2294–9.
doi:10.1182/blood-2002-07-2297
195. Sinha ML,Fry TJ,Fowler DH,Miller G,Mackall CL. Interleukin 7 worsens graft-
versus-host disease. Blood (2002) 100(7):2642–9. doi:10.1182/blood-2002-04-
1082
196. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-
7 administration to humans leads to expansion of CD8+ and CD4+ cells but a
relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 29(3):313–9.
doi:10.1097/01.cji.0000210386.55951.c2
197. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Admin-
istration of rhIL-7 in humans increases in vivo TCR repertoire diversity by pref-
erential expansion of naive T cell subsets. J Exp Med (2008) 205(7):1701–14.
doi:10.1084/jem.20071681
198. Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB,
et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recov-
ery after allogeneic stem cell transplantation. Blood (2012) 120(24):4882–91.
doi:10.1182/blood-2012-06-437236
199. Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannu-
rita S, et al. Human IL2RA null mutation mediates immunodeficiency with
lymphoproliferation and autoimmunity. Clin Immunol (2013) 146(3):248–61.
doi:10.1016/j.clim.2013.01.004
200. Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F. Adjuvant
interleukin-2 therapy for patients refractory to donor lymphocyte infusions.
Exp Hematol (2004) 32(2):218–23. doi:10.1016/j.exphem.2003.10.016
201. Inamoto Y, Fefer A, Sandmaier BM, Gooley TA, Warren EH, Petersdorf SH,
et al. A phase I/II study of chemotherapy followed by donor lymphocyte infu-
sion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoi-
etic cell transplantation. Biol Blood Marrow Transplant (2011) 17(9):1308–15.
doi:10.1016/j.bbmt.2011.01.004
202. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-
dose interleukin-2 therapy restores regulatory T cell homeostasis in patients
with chronic graft-versus-host disease. Sci Transl Med (2013) 5(179):179ra43.
doi:10.1126/scitranslmed.3005265
203. Verneris MR. T-Cell Depleted Double UCB for Refractory AML (NCT01464359)
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) (2013)
[updated 2013 Oct 31; cited 2013 Nov 01]. Available from: http://clinicaltrials.
gov/ct2/show/NCT01464359
204. Alpdogan O, Eng JM, Muriglan SJ, Willis LM, Hubbard VM, Tjoe KH, et al.
Interleukin-15 enhances immune reconstitution after allogeneic bone mar-
row transplantation. Blood (2005) 105(2):865–73. doi:10.1182/blood-2003-
09-3344
205. Goldberg GL, King CG, Nejat RA, Suh DY, Smith OM, Bretz JC, et al.
Luteinizing hormone-releasing hormone enhances T cell recovery following
allogeneic bone marrow transplantation. J Immunol (2009) 182(9):5846–54.
doi:10.4049/jimmunol.0801458
206. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, et al. Reversible
inhibition of testicular steroidogenesis and spermatogenesis by a potent
gonadotropin-releasing hormone agonist in normal men: an approach toward
the development of a male contraceptive. N Engl J Med (1981) 305(12):663–7.
doi:10.1056/NEJM198109173051203
207. Kelly RM, Highfill SL, Panoskaltsis-Mortari A, Taylor PA, Boyd RL, Hollander
GA, et al. Keratinocyte growth factor and androgen blockade work in concert
to protect against conditioning regimen-induced thymic epithelial damage and
enhance T-cell reconstitution after murine bone marrow transplantation. Blood
(2008) 111(12):5734–44. doi:10.1182/blood-2008-01-136531
208. Murphy WJ, Durum SK, Longo DL. Role of neuroendocrine hormones in
murine T cell development. Growth hormone exerts thymopoietic effects
in vivo. J Immunol (1992) 149(12):3851–7.
Frontiers in Immunology | Alloimmunity and Transplantation February 2014 | Volume 5 | Article 68 | 18
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danby and Rocha Improving umbilical cord blood transplantation
209. Chen BJ, Cui X, Sempowski GD, Chao NJ. Growth hormone accelerates
immune recovery following allogeneic T-cell-depleted bone marrow trans-
plantation in mice. Exp Hematol (2003) 31(10):953–8. doi:10.1016/S0301-
472X(03)00196-6
210. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, Owzar K, et al.
Growth hormone mitigates against lethal irradiation and enhances hemato-
logic and immune recovery in mice and nonhuman primates. PLoS One (2010)
5(6):e11056. doi:10.1371/journal.pone.0011056
211. Kooijman R, Scholtens LE, Rijkers GT, Zegers BJ. Type I insulin-like
growth factor receptor expression in different developmental stages of
human thymocytes. J Endocrinol (1995) 147(2):203–9. doi:10.1677/joe.0.
1470203
212. Alpdogan O, Muriglan SJ, Kappel BJ, Doubrovina E, Schmaltz C, Schiro R,
et al. Insulin-like growth factor-I enhances lymphoid and myeloid reconsti-
tution after allogeneic bone marrow transplantation. Transplantation (2003)
75(12):1977–83. doi:10.1097/01.TP.0000070167.81584.A2
213. Min D, Taylor PA, Panoskaltsis-Mortari A, Chung B, Danilenko DM, Farrell
C, et al. Protection from thymic epithelial cell injury by keratinocyte growth
factor: a new approach to improve thymic and peripheral T-cell reconsti-
tution after bone marrow transplantation. Blood (2002) 99(12):4592–600.
doi:10.1182/blood.V99.12.4592
214. Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL,Weinberg KI, et al. Ker-
atinocyte growth factor preserves normal thymopoiesis and thymic microen-
vironment during experimental graft-versus-host disease. Blood (2002)
100(2):682–91. doi:10.1182/blood.V100.2.682
215. Min D, Panoskaltsis-Mortari A, Kuro OM, Hollander GA, Blazar BR, Weinberg
KI. Sustained thymopoiesis and improvement in functional immunity induced
by exogenous KGF administration in murine models of aging. Blood (2007)
109(6):2529–37. doi:10.1182/blood-2006-08-043794
216. Rossi SW, Jeker LT, Ueno T, Kuse S, Keller MP, Zuklys S, et al. Keratinocyte
growth factor (KGF) enhances postnatal T-cell development via enhance-
ments in proliferation and function of thymic epithelial cells. Blood (2007)
109(9):3803–11. doi:10.1182/blood-2006-10-049767
217. Wang Y, Chen G, Qiao S, Ma X, Tang X, Sun A, et al. Keratinocyte growth factor
enhanced immune reconstitution in murine allogeneic umbilical cord blood
cell transplant. Leuk Lymphoma (2011) 52(8):1556–66. doi:10.3109/10428194.
2011.573037
218. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, et al.
Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-
versus-host disease (GVHD) after allogeneic hematopoietic stem cell trans-
plantation (HSCT). Blood (2006) 108(9):3216–22. doi:10.1182/blood-2006-
04-017780
219. Rizwan R, Levine JE, Defor T, Ferarra JL, Weisdorf DJ, Blazar BR, et al. Peri-
transplant palifermin use and lymphocyte recovery after T-cell replete, matched
related allogeneic hematopoietic cell transplantation. Am J Hematol (2011)
86(10):879–82. doi:10.1002/ajh.22136
220. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van
den Brink MR, et al. Palifermin is efficacious in recipients of TBI-based but
not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone
Marrow Transplant (2013) 48(1):99–104. doi:10.1038/bmt.2012.115
221. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of
a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-
versus-host disease (GVHD) after related donor allogeneic hematopoietic cell
transplantation (HCT). Biol Blood Marrow Transplant (2008) 14(9):1017–21.
doi:10.1016/j.bbmt.2008.06.013
222. Kenins L, Gill JW, Boyd RL, Hollander GA, Wodnar-Filipowicz A. Intrathymic
expression of Flt3 ligand enhances thymic recovery after irradiation. J Exp Med
(2008) 205(3):523–31. doi:10.1084/jem.20072065
223. Wils EJ, Braakman E, Verjans GM, Rombouts EJ, Broers AE, Niesters HG,
et al. Flt3 ligand expands lymphoid progenitors prior to recovery of thy-
mopoiesis and accelerates T cell reconstitution after bone marrow transplan-
tation. J Immunol (2007) 178(6):3551–7.
224. Fewkes NM, Krauss AC, Guimond M, Meadors JL, Dobre S, Mackall CL.
Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition
enhances marrow and thymic engraftment after hematopoietic stem cell trans-
plantation. Blood (2010) 115(20):4120–9. doi:10.1182/blood-2009-10-248898
225. Kelly RM, Goren EM, Taylor PA, Mueller SN, Stefanski HE, Osborn MJ,
et al. Short-term inhibition of p53 combined with keratinocyte growth fac-
tor improves thymic epithelial cell recovery and enhances T-cell reconstitu-
tion after murine bone marrow transplantation. Blood (2010) 115(5):1088–97.
doi:10.1182/blood-2009-05-223198
226. Merindol N, Charrier E, Duval M, Soudeyns H. Complementary and contrast-
ing roles of NK cells and T cells in pediatric umbilical cord blood transplanta-
tion. J Leukoc Biol (2011) 90(1):49–60. doi:10.1189/jlb.0111007
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 11 November 2013; paper pending published: 18 January 2014; accepted: 07
February 2014; published online: 24 February 2014.
Citation: Danby R and Rocha V (2014) Improving engraftment and immune
reconstitution in umbilical cord blood transplantation. Front. Immunol. 5:68. doi:
10.3389/fimmu.2014.00068
This article was submitted to Alloimmunity and Transplantation, a section of the
journal Frontiers in Immunology.
Copyright © 2014 Danby and Rocha. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org February 2014 | Volume 5 | Article 68 | 19
